🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Novartis AG (SWX:NOVN)
Switzerland flag Switzerland · Delayed Price · Currency is CHF
127.76
+0.52 (0.41%)
Nov 20, 2026, 5:30 PM CET
← View all transcripts

Meet Novartis Management 2026 Part 2

Nov 19, 2026

Summary

Immunology updates highlighted ianalumab’s two-year Sjögren’s results and a multi-billion outlook, alongside Cosentyx’s $8B 2027 target. Leqvio outcomes, oncology franchises and neuroscience programs remain key catalysts, with pivotal data and regulatory discussions ahead.

Fiona Marshall
President of Biomedical Research, Novartis

Okay, so let's get started. Good morning, everybody. My name's Fiona Marshall. I lead biomedical research at Novartis. I'm delighted to introduce our immunology team to you. Richard, maybe you'd like to start.

Richard Siegel
Global Head of Immunology, Novartis

Sure. I'm Richard Siegel. I'm the research head in immunology. I'm a rheumatologist, immunologist, and been in Novartis eight years, first in translational medicine, heading the immunology group, and for the last three years, heading the research group in Basel. Very nice to see you all.

Angelika Jahreis
Global Head of Immunology Development, Novartis

Hi, my name is Angelika Jahreis. I lead development for immunology at Novartis. I am a dermatologist physician scientist and have been leading the development unit for the last six years at Novartis. Nice to see you all.

Christy Siegel
SVP and Therapeutic Area Head of Immunology, Novartis

Good morning. My name is Christy Siegel, not related to Richard Siegel, despite the same spelling, and I lead commercialization in the U.S. for our immunology portfolio. Happy to be here.

Fiona Marshall
President of Biomedical Research, Novartis

Okay, just a few introductory comments and then obviously hand over to the team. For me, there is really three things that define Novartis immunology. One is that we really do go deep on the science. As you will hear about, we are really willing to be pioneers into disease areas of high unmet need where there may be no current treatments, and we can leverage multiple modalities that can really target the core drivers of the disease. Areas I think you might want to ask about, Cosentyx, it continues to be a remarkable medicine, and it does keep delivering, and most recently with polymyalgia rheumatica as a further growth indicator. Then, of course, the successful launch of Rhapsido, and really the importance of this new medicine for patients with allergic diseases such as CSU and CIndU.

Ianalumab, the first drug to demonstrate positive phase III effects in Sjögren's disease, and of course, with continuing data really demonstrating the benefit of this for patients. Also ianalumab going into other indications in SLE, lupus nephritis, and systemic sclerosis. The other area is this remarkable efficacy we have seen with the concept of immune reset with B-cell depletion. First of all, with YTB323, but we are now profiling a range of different modalities to really try to achieve the optimal risk benefit across different patients with autoimmune diseases. Having a deep understanding of the underlying disease mechanisms and the drivers is really at the heart of what we do across all the diseases in biomedical research. Increasingly, our portfolio is very set on understanding the core drivers and targeting those core drivers in disease, and we think that is where you can get the most meaningful benefit.

That understanding has been applied to BTK inhibition with remibrutinib and has really allowed us to take it across so many different indications. Understanding where there can still remain unmet need, both for individual patients, but also unresponsive patients in the population, is increasingly at the face of what we are doing in the immunology area, especially where you may think there are already effective treatments. It allows us to build on known mechanisms and then add in additional mechanisms that can really then address that unmet need. That is what really driving a number of drugs in our portfolio that we can talk about, hitting multiple orthogonal pathways usually to get that added efficacy. That is what underpins our strategy for the choice of bispecific antibodies, and in diseases like atopic dermatitis.

As you have already seen and heard from Vas, the portfolio really does cover pretty much all the modalities you could possibly think about, and this allows us really then to target all aspects of the disease. We were the pioneer in CAR-T and oncology, of course, and that allowed us to pivot very quickly YTB from oncology into autoimmune disease, and also our expertise in T-cell engagers, again, coming from oncology going into autoimmune disease. Now we have actually generated a new generation of modalities, for example, T-cell engagers that are now optimized for immunology rather than CAR-T, and looking for in vivo CAR-T that would be most appropriate in the autoimmune disease.

Now, I have mentioned it already, but I think for me, Novartis really does stand out as being a pioneer in disease, and Sjögren's is an incredible example of this, a really serious disease with very high unmet need, and we were willing to go where others hadn't or had tried and failed. We pursue these diseases because we really deeply understand some of the underlying biology, and we think there's new science we can take into it, and because we think the patient need justifies it. It's that willingness to be first is actually a deliberate part of our strategy. We're constantly looking for those types of opportunities. Another real highlight, and Richard and Angelika Jahreis are involved in these. Actually, Richard came from our translational medicine team, was running clinical trials before I enticed him into the research, so has deep, deep real understanding of the clinical trials.

One of the things we do is the platform trials, where we have an ongoing trial and we put in multiple different mechanisms one after the other, and we've done this particularly in HS. That allows us to compare different mechanisms, and really then select which ones are the most best ones for us to take forward, but it also gives us a real understanding of the pathways underlying disease. So, just to close out, and I'll hand you to the team, it is all this combination that gives us the confidence now to replace Cosentyx as it comes up to its loss of exclusivity. Obviously, Rhapsido already launched, ianalumab now first in disease, with that phase III data, and Remi and our B-cell portfolio, B-cell reset portfolio.

Cosentyx gives us that real commercial infrastructure that Christy Siegel can tell you about, and that credibility then to launch each of these programs, I think, really well. So with that, very much open to questions.

Sachin Jain
VP, Bank of America

Can I take that? I've got the mic.

Fiona Marshall
President of Biomedical Research, Novartis

Okay, you've got the microphone.

Sachin Jain
VP, Bank of America

Sorry. Sachin Jain, Bank of America. I'll take two if I may. First one will be to follow on from the question asked in the main session on ianalumab in Sjögren's. Perhaps you could just flesh out what Vas was trying to say on the label discussions. I got a little bit confused by what characterization section 14 is, and are we talking about subgroups of the overall population here and how that would impact commercialization?

Fiona Marshall
President of Biomedical Research, Novartis

All right. Maybe, Angelika, we can start with you, and maybe say a little bit more about the Sjögren's trial and the measures of ESSDAI, and I think this helps to then lead on to the response to your question.

Angelika Jahreis
Global Head of Immunology Development, Novartis

Yeah. Thank you, Fiona. Let me start out maybe with ACR, where I have never seen as many sessions about Sjögren's disease as this ACR. So there is incredible excitement and interest in the community to really understand this disease and understand the treatments that are available for coming forward for this disease. Ianalumab is the first molecule that has ever shown efficacy on systemic manifestations of the disease, as measured by ESSDAI, across two adequate and well-controlled studies. We have now presented Let me maybe just highlight some data we have presented this year at ACR, because Vas also talked about that. The ESSDAI is a measurement of systemic involvement that could be pneumonitis in the lung, could be arthritis in joints, could be nephritis in the kidneys, or peripheral or central neuropathy. So, really severely sick patients.

The patients we included in our trial were patients who had an ESSDAI of 12.5 approximately across the different treatment arms. These patients, after two years of being on ianalumab, went to an ESSDAI of five, which is mild disease. So they went from moderate to severe disease, being pretty much at the edge of severe disease, going down to mild disease. 23% of patients, we have shown these data at the ACR this year, after two years on ianalumab, had a zero score on ESSDAI, meaning they had no more systemic disease. That is a major impact for patients. I just want you to realize that this is what the patient can expect to experience after two years on ianalumab.

In addition, we have seen that we have a consistent effect across patient-reported outcomes, dryness is one of these outcomes that is really important to patients. While the studies were focused on enrolling patients with systemic manifestations, some of them also had dryness, we have been able to reduce dryness in patients as well as patient global outcomes, physician global outcomes. We have been able to reduce these patient and physician-reported outcomes as well. Importantly, when it comes to salivary flow, because one of the organs that is affected in Sjögren's, maybe you, Richard, you can add a little bit of the scientific data, is the salivary glands. What we have seen in these data is patients who still have residual activity, ianalumab restores their ability to produce saliva and reduces then the symptom of dryness. So, really important data for patients.

For the FDA, just one last point.

Fiona Marshall
President of Biomedical Research, Novartis

Also, we need to come on to the labeling.

Angelika Jahreis
Global Head of Immunology Development, Novartis

Yes.

Fiona Marshall
President of Biomedical Research, Novartis

Specifically.

Angelika Jahreis
Global Head of Immunology Development, Novartis

Exactly. For the FDA interactions specifically, this is also the first time we are having discussions with the FDA. FDA has ever seen a molecule for Sjögren's disease, because this is the first drug that has ever achieved the primary endpoint across two trials. We have had discussions with FDA. They've asked a lot of questions, including around what are the subsets of patients that respond the best, and we have been working with them to address their questions. How exactly the label will look like, that is something that we are still working with the FDA, and we currently don't have more details.

Fiona Marshall
President of Biomedical Research, Novartis

Okay. Do you want to just comment on that from the commercial side? I mean, I'll just say one thing here. I mean, it's not surprising in a way that the more severe patients have the most benefit. I mean, that actually applies to most drugs. On the other hand, we think there is real benefit going in the earlier patients, because they actually have the capability of actually even sort of regenerating some salivary flow. That's why there's the sort of discussions, I think, just to give it a bit more color around how the FDA are thinking.

Christy Siegel
SVP and Therapeutic Area Head of Immunology, Novartis

Yeah. Maybe just from a commercial perspective, to build on Angelika's comments, the patient that we're targeting is a patient who has dryness plus signs of these other systemic involvement, whether they be organ or otherwise. That's important, and that's actually what we've been doing, is spending time building the market to help understand even systemic disease over symptomatic disease. If you just look, for those of you who have been to ACR just over the last three years, how much of a shift we've seen even in the understanding, the relevance, the interest in Sjögren's disease, but also the understanding of, like, three years ago, it was like, "Well, what is ESSDAI?" To this year, people are actually getting prepared to actually measure ESSDAI, if that's required commercially moving forward. I would say to Angelika's point, a lot of interest.

In addition to what she mentioned in terms of disease control and symptom burden, I think the other important dimension of our two-year data is that we showed safety. That's really important to the rheumatology community, is long-term safety, because that in and of itself, we believe, makes them more likely to want to actually try ianalumab in their patients.

Fiona Marshall
President of Biomedical Research, Novartis

Okay.

Florent Cespedes
Analyst, Oddo BHF

Thank you very much. Good morning. Florent Cespedes from Oddo BHF. A question on the bispecific IL-13, IL-18. Could you maybe share with us how you believe the product should be differentiated? Because IL-18 seems to broaden the eligible population. There will be also, we understand, something on the convenience with a more, let's say, convenient injection regimen. Anything on the upcoming clinical trials? Is there any head-to-head trials which should be conducted to better understand and better position the product versus the existing drugs?

Fiona Marshall
President of Biomedical Research, Novartis

Maybe you can talk about the biology here.

Richard Siegel
Global Head of Immunology, Novartis

Yeah. We are really pleased to now talk about the biology of IL-18/13. IL-18 is a cytokine that we know well. We actually have it as a component of arumakimig, the IL-1β/IL-18 bispecific. It is originally thought to be a kind of pro-inflammatory cytokine, not specifically related to allergic conditions. But we, in our labs, had shown that IL-18 actually is a cofactor for TH2 development. So it is both upstream and parallel to IL-13. So we found it a very compelling target for atopic dermatitis, and then other competitors showed monotherapy efficacy. So you have the kind of two components, orthogonal biology plus single agent efficacy. We did a small trial actually ourselves with IL-18 monotherapy with the IL-18 arm.

We think it is really well-suited for the goal of just increasing the efficacy bar, which I think is what everybody wants in atopic dermatitis, combined with the half-life extension that makes a really compelling proposal. We will talk more about that molecule, but just to tell you that this is only the tip of the iceberg in our bispecific program. We have multiple other bispecifics coming addressing different aspects of atopic dermatitis.

Fiona Marshall
President of Biomedical Research, Novartis

Angelika, do you want to say a bit about the next, where we go here with the next trials?

Angelika Jahreis
Global Head of Immunology Development, Novartis

Yeah. So we conducted this phase II-B study based on the evidence from the IL-18 study, and we are really thrilled that we see higher efficacy with respect to EASI outcomes for this modality. Yes. So with these data, we are now going to start phase III trials. We are in interactions with the health authorities so that these studies are well-vetted. Certainly, we understand that we need to profile this molecule, and it is for patients, physicians, and payers to be superior to currently available therapies. Based on the phase II-B data, we have good confidence, and we are thinking through how to exactly do this and aligning this with the health authorities.

Steve Scala
Analyst, TD Cowen

Thank you very much. I'm Steve Scala from TD Cowen. Investors have pretty big expectations for ianalumab in Sjögren's, but you're using words like subset. Subset means narrow. So what sort of reassurance can you provide us based on your knowledge of what this discussion is all about, that when the final label comes out, we're not going to have a substantially reduced opportunity here than investors now envision? So that's the first question. The second question is on Cosentyx. $8 billion seems like a really long way from where we are now to achieve in 2027, at least for me. So what are we missing? What's going to happen next year that's going to tack on $800 million to Cosentyx? Thank you.

Fiona Marshall
President of Biomedical Research, Novartis

Christy, do you want to take those two?

Christy Siegel
SVP and Therapeutic Area Head of Immunology, Novartis

Sure. So regarding Ianalumab, I can say that we remain confident in our multi-billion dollar outlook on Ianalumab for Sjögren's disease, full stop. I mean, this is a large patient population. There is high unmet need. I think it will be a steady ramp-up, to be honest with you, because of the level of development needed with the disease itself. But there is interest because there is nothing else to treat these patients, and I think that's really important, especially given we have a subcutaneous delivery system as well as the safety profile we have. So that's what gives us confidence, plus our infrastructure.

Fiona Marshall
President of Biomedical Research, Novartis

I mean, just something on the Ianalumab.

Christy Siegel
SVP and Therapeutic Area Head of Immunology, Novartis

Yeah.

Fiona Marshall
President of Biomedical Research, Novartis

I mean, the thing is that the physicians don't use ESSDAI themselves. So actually, to have an ESSDAI specification on the label doesn't make sense in clinical practice. So in reality, we actually think that once physicians start using it and see the benefit, that they're probably not going to restrict patients from getting access to it. But Angelika, maybe you've got some thoughts on that.

Angelika Jahreis
Global Head of Immunology Development, Novartis

Yeah. I mean, from my side, I can say that the patients we have enrolled in the trial are patients that are in need of better therapies. And like every time we interact with FDA tries to understand where does the benefit lie. I have not seen, we haven't seen the label that FDA is proposing. It is the first time health authorities have the opportunity to look at data for Sjögren's disease and have to decide how to draft a label. In those patients that have the highest disease burden, we have also seen the highest benefit, which is a very good sign because that suggests that it really works in patients with Sjögren's disease. And I am as confident as Christy is to say that this is a desperately needed therapy for Sjögren's patients, and there are many patients out there waiting for this therapy.

Fiona Marshall
President of Biomedical Research, Novartis

Okay. And of course, there's the other indications still coming. Let's just quickly go to the Cosentyx question.

Christy Siegel
SVP and Therapeutic Area Head of Immunology, Novartis

Yes. So what do we see in Cosentyx? I think we have very good momentum in Cosentyx, in particular with our HS indication, where we are the market leader, both in terms of NBRx and naive market share. We continue to be the number one IL-17 in the SpA space, and I believe we'll have a halo, frankly, from the PMR launch, our 11th indication in 11 years on the market with Cosentyx. So I also believe that PMR will help us grow, specifically in 2027. I will also temper that to say, just appreciating that PMR is coming later in our life cycle, and advanced therapy use is pretty small today. So it will take some time to develop the advanced therapy market, specifically in PMR. Last but not least, we have really good We're the leading IL-17 in terms of market access.

So those things all taken together give us the confidence that we will deliver the $8 billion in 2027.

Fiona Marshall
President of Biomedical Research, Novartis

Do you want to come down the center so that some people on this side of the room And also, I want to just try and get some more questions.

Christy Siegel
SVP and Therapeutic Area Head of Immunology, Novartis

Okay.

James Gordon
Analyst, Barclays

Thank you.

Thanks. It's James Gordon from Barclays. Two questions on Remi, please. One was on food allergy. I think you started the trial now, and it's just against placebo. What is a good result looking like when you get that? It sounded like Vas was quite excited, but you'd be up against biosimilar Xolair and GSK's probably more convenient version of Xolair as well. Do you think that you can actually beat or meet it, or is it just about being oral, and that's a big advantage even if it's against, say, three monthly products? Then just on Remi HS, in the phase II, I noticed there was quite a big difference in the Hurley stage III across the three arms. It was much lower in the low dose, a bit higher in the high dose, and even higher in the placebo arm.

Do you think drugs would work better or less well in Hurley III versus II, and could that have been a factor in the efficacy?

Fiona Marshall
President of Biomedical Research, Novartis

Okay, let's start with food allergy.

Angelika Jahreis
Global Head of Immunology Development, Novartis

Food allergy, we are very excited about. Vas has shown the data on Remi, and it is the same mechanism or similar mechanism of action as we have seen in CSU and CIndU. So also from biology, this is an indication with a very strong biology behind it. The data, if you look at Xolair peanut allergy, obviously from a much larger study, but they are certainly very encouraging because we are seeing higher levels of response with our higher dose. That gives us a lot of confidence when we go into phase III, which is a program that is designed to give us an allergen-agnostic label, because we will be testing several allergens.

Today, we think that we can address probably 3.7 million patients who have multiple allergens and have had severe or serious anaphylactic reactions, out of the 220 million patients who actually have food allergy in general.

Fiona Marshall
President of Biomedical Research, Novartis

Do you want to go onto the HS question?

Angelika Jahreis
Global Head of Immunology Development, Novartis

HS question, yes, absolutely. So HS, we-

Fiona Marshall
President of Biomedical Research, Novartis

Dose response curve as well.

Angelika Jahreis
Global Head of Immunology Development, Novartis

Yes. From what we have seen, that we are probably at the plateau of the dose response in phase II. It was a relatively small study coming from a platform, as Fiona Marshall has described. Exciting that we got readout for this study from a platform study. We have seen probably that we are at the top of the dose response with the 25 milligram. The spread was 15 to 35 delta on the high score, which is a relatively robust response on the top level of what has been seen. I agree with you. Typically, we see similar to what I have said about Sjögren's disease, that those with the highest disease have the best response there as well.

Fiona Marshall
President of Biomedical Research, Novartis

Yeah. Richard Siegel, do you want to just add on there?

Richard Siegel
Global Head of Immunology, Novartis

Just to add, I think one of the reasons we were very excited about remibrutinib is the same reason that CSU has been so successful, is the rapid onset of action. As you may know, for Xolair and food allergy, it takes weeks to months to get patients to be more tolerant or protected from anaphylaxis. But we believe that we have seen in the food challenge part of the phase II rapid onset of action, and we think that is going to be important. Just to highlight that we have an asset that we just acquired, the Xolair anti-IgE dissociator, that has the potential to do what Remi could do with rapid onset of action, because it dissociates IgE from its receptor, which is something that is never been biologically possible before in a biologic.

That is coming after, but this rapid onset of action is really important to food allergy patients who do not want to have to start planning for, say, a vacation where they might have peanut exposure three months ahead of time. We know that from our clinical colleagues.

Graham Parry
Analyst, Citi

Thanks. Graham Parry from Citi. Just following on remibrutinib. Could you just talk to the comparability of the statistical methods that were used in the phase II and the phase III studies, and also across the Cosentyx and Bimzelx studies? Because I think the market is trying to compare the response rates. If you could perhaps explain how antibiotic rescue therapy was treated, whether you are using non-responder imputation or multiple imputation, and does that flatter your phase II relative to the design of phase III? Are there any key differences you would flag versus Bimzelx? Thank you.

Angelika Jahreis
Global Head of Immunology Development, Novartis

Yeah, very astute question, and I want to focus that response maybe on our phase III data readouts that are coming and share with you how we have done it for this one. What I can share with you as well, and you may have seen that, is that from the external pipeline, placebo rates have increased in the latest readouts for hidradenitis suppurativa, and that is somewhat of a concern for HS studies in principle. In our phase III program, there are several ways of- several interfering events, and one of them could be use of antibiotics. We have guided our investigators not to use anti-inflammatory antibiotics. The efficacy of antibiotics in HS is not the antibiotic mechanism of action that they kill bacteria, but it is the anti-inflammatory mode of action. We have guided them for non-HS-related infections not to use anti-inflammatory antibiotics.

We have very conservative imputation methods for use of antibiotics for HS, so that in this program, as well as for use of intralesional steroids, as well as for decapitation of abscesses. All three of them are imputed in a very conservative way. That gives us confidence that with respect to addressing potential bias here and potentially increased placebo rates, that we have addressed this aspect within our phase III trials.

Graham Parry
Analyst, Citi

Thank you.

Naresh Chouhan
Founder, Intron Health

Hi. Just a couple of questions on going back to Cosentyx, please, in HS in the U.S. Vas had said that the market wasn't growing very much, I think, last year. Are you now seeing the market growing, or is the majority of your growth coming from share gains? Secondly, my understanding is that HS patients are over-indexed in Medicaid. Any insights on your Medicaid exposure? I'm just thinking about IRA impact, given the higher price in HS in 2028.

Christy Siegel
SVP and Therapeutic Area Head of Immunology, Novartis

Yep. Maybe on your first question, actually, the HS growth rate is, I would say, mid-teens, roughly 15%. When we're the market leader, we're holding our own in terms of market leadership in HS for Cosentyx, and as the market expands, our growth expands alongside that. That is our objective, to maintain that leadership as we move forward in a market that will continue to expand. I think to your point, one thing we learned, and we think about that across the portfolio, as we expected, as more competition came in, that the market would continue to explode in demand, like we saw with Cosentyx, but that was not the case. We've seen, since other entrants have come, just kind of a ramp-up, and then it just stays there for a while until the next competition comes. Ramp-up, but very not explosive, I would say.

Pretty steady growth, and that's where we talk about moderate growth. Even when we think about Remi HS, in my opinion and experience, I think that's where we have to, even though we have an amazing profile, being a fast onset oral, and because it's an oral, it'll be potentially used right after antibiotics, what's going to be important is how fast will that market grow? I'm just saying that because I think how we think about it is, yes, we're with Cosentyx today in HS, but we also think about how does that affect our future and how are we leveraging the portfolio overall, and our understanding for the benefit of patients and the business. Now, to your second question around Medicaid exposure for Cosentyx, it's a pretty small part, actually, of our business overall. It's roughly 10%.

Angelika Jahreis
Global Head of Immunology Development, Novartis

Can I add on top of that, Christy? I want to make sure you are all aware that we got just approval for Cosentyx HS I.V., as well as for Cosentyx adolescents. These are two additional important approvals for us with respect to Cosentyx and hidradenitis suppurativa.

Pete Verdult
Analyst, BNP

Thanks. Pete Verdult, BNP. Just a couple of questions, maybe back to Richard or Fiona. When we talk about immune reset, tip of the iceberg, with respect to your bispecifics, was it a conscious decision to go forward with IL-13/18 versus other plausible combinations like IL-13/17? Just interested in your preference for the combinations there. Then, sorry, Angelika Jahreis, for you, just to harp on about Remi in HS. Is the right way of thinking about this, is Remi in HS like OTEZLA in psoriasis, where you have got an oral that perhaps is not the best efficacy, but it is still going to be frontline use, easily prescribed? Or is there still an ambition within Novartis that you can match? I think everyone, you may disagree, but the market believes bimekizumab has got the best efficacy.

Is the ambition of Novartis to match that or just be the OTEZLA of HS?

Fiona Marshall
President of Biomedical Research, Novartis

Well, maybe I will start on the bispecific. I will start, then you, because it is more of a general principle, because I think you have touched on something. There are companies or approaches where you just make, especially now with very high throughput capabilities, a sort of I have even seen 100,000 bispecific combinations that you then put into a million different assays to profile. Obviously, that is one way of doing it, but that will take you a very long time to get to the right answer. I think going back to my sort of deep disease area understanding, I think this is where we have really applied that knowledge to how we have selected the bispecifics in immunology. But, you know,

Richard Siegel
Global Head of Immunology, Novartis

Yeah. So, I think it was a deliberate decision to look for combinations with known MOAs. Most of the bispecifics that you are going to see are known by novel, meaning we are not going with novel-novel. That would be more risky. We validate through not only immune cell profiling, but in tissue, spatial transcriptomics, and other techniques to say, "Are the right cells making the right cytokines in the tissue of HS patients?" So, we have a number of collaborations looking very deeply at HS tissue at the cellular level and molecular level. I think that is the basic principles, as Fiona Marshall said. The other aspect of atopic is the different types of issues that you have. You have itch, you have skin barrier, and you will see bispecifics tailored to some of those important needs.

So, but 1318 is really an attempt over the entire population of atopic to raise the efficacy ceiling, which is really one of the key problems with current therapies, that half the patients are not adequately responding.

Fiona Marshall
President of Biomedical Research, Novartis

Okay. The second part of the question.

Angelika Jahreis
Global Head of Immunology Development, Novartis

I wanted to go back to your question about hidradenitis suppurativa and remibrutinib, and what is our ambition. Remibrutinib is an oral therapy with fast onset of action and an exceptional safety profile. We have not seen any liver safety events, and we do not have a boxed warning. In that context of HS, that is important because many of the patients, and as a dermatologist, I have treated many patients with HS, these are young women, often overweight, often risk factors for adverse events. Many of these patients, I think, would benefit and would prefer an oral drug. I believe that an oral drug could come before biologics, and therefore, a more modest benefit or efficacy would also be acceptable to these patients. Now, I want to say we will see these data with both studies reading out soon, and then we will share the data with you.

It is just a matter of a few more weeks.

Fiona Marshall
President of Biomedical Research, Novartis

Thank you.

Simon Baker
Analyst, Rothschild

Thank you. Simon Baker from Rothschild. Continuing on the HS theme and market share dynamics, you are holding leading market share at the moment. Are you confident you can sustain that in the face of bimekizumab? Because as Pete was suggesting, there is a perception that that is the superior drug. Or is this simply a reflection of the breadth of indications that Cosentyx has? Being very good in lots of things is more important than being best in a few because of the rebate wall dynamics. Is that really the key factor that is supporting that confidence? Then going back to IL-13/18, I just wonder if you could give us a little bit more detail on the potential scope for extended half-life from the technology or just the intrinsic characteristics of the molecule, and what the ideal half-life is in terms of commercial profile.

Is it simply longer is always better, or is there, in your view, an optimum dosing frequency there? Thank you.

Christy Siegel
SVP and Therapeutic Area Head of Immunology, Novartis

So, how about I start on HS, then we can pass off for the next part of the question, then I can close on that. For HS, my expectation is that we will continue to be the market leader, specifically in naive market. That is important because that is the majority of the market in HS, is naive patients, not the switch marketplace. I would say there are two reasons for that. First, we have a strong safety and efficacy profile and a high degree of familiarity with the dermatology community. The second piece is our position in terms of formulary and market access. That just helps reinforce a clinical decision to use Cosentyx first line.

Fiona Marshall
President of Biomedical Research, Novartis

Right. Then do you want to cover the, is it-

Richard Siegel
Global Head of Immunology, Novartis

Yeah. I can start with the basic part, but I think a number of different doses were used. Half-life extension is an art as much as a science. We use Fc engineering. However, what we know is that the same Fc engineering with different binders comes out differently. GHC is quite favorable, and that led to the potential of every two or every three months dosing. I think some different regimens were tried in the phase II, if you want to comment, Angelika.

Angelika Jahreis
Global Head of Immunology Development, Novartis

Yeah. In the phase II, we have tested different regimens with every four-week testing. Based on these data, we believe that when we go forward now into phase III, that we will extend that to eight-weekly or 12-weekly dosing in the maintenance phase of these trials. So, we are quite confident that this is a therapy that also significantly reduces the number of injections for patients with atopic dermatitis.

Fiona Marshall
President of Biomedical Research, Novartis

Any more? Steve's got another question at the front.

Steve Scala
Analyst, TD Cowen

Thank you. I have a question about clinical trials in general. Investors and companies seem to look at data generated in China with some caution or even suspicion. I am wondering if you have ever personally witnessed data that could not be replicated in a Novartis lab, or if you have seen data irregularities or anything odd about data generated in China. If you haven't, then why aren't you doing more trials there, since they can be done less expensively and more quick?

Fiona Marshall
President of Biomedical Research, Novartis

Do you want me to answer this one? I'll start. I mean, we are a global company, and we do trials all over the world all the time. Angelika, you can. Especially for these big populations, that's how we can recruit the most people most quickly. Also, quite often it's our intention to launch medicines in as many countries as possible. That's why we're top of the medicines access list. In any global trial, of course, you see sites where there are things that haven't necessarily met the standards. That's just normal. Occasionally you see that in China, but we see it in other places as well. One thing is important is we set the same, very same, very high quality, and all ethical. Everything we set, we run to global standards around the world.

Steve Scala
Analyst, TD Cowen

May I follow up? Do you see more of those situations in China than, say-

Fiona Marshall
President of Biomedical Research, Novartis

No, I wouldn't say that that's the case.

Steve Scala
Analyst, TD Cowen

Why aren't you doubling, tripling the numbers?

Fiona Marshall
President of Biomedical Research, Novartis

Well, now we are, of course, we're increasing where we do trials depending on the molecules and where the patients are.

Angelika Jahreis
Global Head of Immunology Development, Novartis

Yeah. I want to build on that. If you look through our clinical trials and where we do trials, we recruit a significant number of patients in China, but all our trials in China are also done, as Fiona Marshall has said, due to our Novartis standards. Yeah. We are going to do even more trials in China.

Steve Scala
Analyst, TD Cowen

Yeah.

Fiona Marshall
President of Biomedical Research, Novartis

Okay.

Pete Verdult
Analyst, BNP

Pete Verdult at BNP. Can we stay on just the thematic of clinical trials? Because Angelika Jahreis, you made a point that others in the industry do as well, which is the execution of clinical trials gets tougher, particularly in immunology because of the rising placebo response rates, the type of patients you're getting. I mean, we've seen high-profile failures where clinical trials have been outsourced to a third party, the execution just hasn't been good, the wrong patients have been recruited. Could you just remind us, the Novartis, do you do a split of when you run your clinical trial organization, do you fully outsource? Do you fully keep it in-house? With this, not myopic, but there's a huge interest in autoimmune diseases, atopic dermatitis, loads of new companies, trispecifics, bispecifics.

Is that just going to be a feature that we need to be aware of, the execution risk of these trials?

Angelika Jahreis
Global Head of Immunology Development, Novartis

We are one of the few pharmaceutical companies that still do studies in-house. We have a large organization that is clinical trial operations, and I do think that is one of the reasons why our studies are executed very well. The design of the trials is very important, and it is something that we need to be very thoughtful about, and we have been very thoughtful about. But certainly something that is a complex task, that why we need to have an excellent workforce, and we do have that. Yeah. I have confidence in the way that our clinical trials are designed, but it is not a trivial task.

Fiona Marshall
President of Biomedical Research, Novartis

I mean, the other thing is the incredible depth of historical data that we have. Although times change and the placebo responses change, standard of care changes, we still have that continuity. We have data42 with all of our historical data in there, and we leverage this. In fact, we are actually using AI, you will hear on the AI panel how we are leveraging AI to further optimize protocols for trials based on our historical data. I think this is another barrier to entry for people that think they can easily come into the area of not having that database to tap into. Okay. A few more questions here.

Pete Verdult
Analyst, BNP

Great. Thank you.

Graham Parry
Analyst, Citi

Thanks. Graham Parry, Citi. I just wanted to follow up, Angelika, about the imputation. You said using conservative imputation. Can you just clarify, is it the same treatment of antibiotics and imputation methods that you used in the Cosentyx studies with the remibrutinib HS? That was a follow-up. Then on inebilizumab, with all this label discussion issue, is there anything in the symptomatic patients trial, the THALASSA study, that could perhaps cover off some of those answers? Is there an opportunity, even if you did have a more restricted label, to perhaps have that expanded later? Then commercially, will it matter anyway? Because if it is a clean, safe drug and there is nothing else, won't docs just try anyway?

Angelika Jahreis
Global Head of Immunology Development, Novartis

We have taken some learnings from the Cosentyx trials and implemented a more conservative imputation methods in the remibrutinib trial. With respect to Sjögren's disease, you are correct that some of our competitors are not doing two trials in the same patient populations, but are splitting it between those that have more symptomatic disease and those who have more systemic disease. We have decided to first look at those with the highest unmet need of systemic disease, but we have initiated and are enrolling, a study that looks at symptomatic patients, so patients who have predominantly dryness. This patient is certainly a study that could be used to enhance the label, should that be necessary.

James Gordon
Analyst, Barclays

Thank you. Can you hear me? Yeah. James Gordon from Barclays. Just on the IL-13/18, looking at the phase II, I think the placebo-adjusted efficacy does not look that different to what Dupixent showed, unless I was misreading it. I think, if I understand correctly, you want to show statistical superiority, but you did something like 47% placebo-adjusted, and Dupixent is also in the 40s range. Is that not a fair comparison because it is something like different patient population, which is why you think you would be superior? Or is it vaguely in the ballpark of Dupixent anyway?

Angelika Jahreis
Global Head of Immunology Development, Novartis

The data from [arumakimig], we are about 10% above the data from dupilumab. I do not know exactly what data you are citing. We think in these data, we clearly see the additive effect of IL-18 on IL-13. Also, as Vas has said, it is a small data set, but we have seen that in those patients who were Dupixent exposed before, we also have the same effect, which typically you would not see, in particular if they were Dupixent inadequate responders and did not respond to Dupixent. We still see the benefit, similar benefit with this dual mechanism of action. We are very excited about the data that we have seen come out of that trial. We will be presenting the data at one of the next dermatology conferences, then we can share all of them together.

Fiona Marshall
President of Biomedical Research, Novartis

Okay, we have got time for one more question.

Speaker 13

Thank you. Holger Blum from [Bellevue Asset Management.] I am grateful for the list of your pipeline, but maybe you can mention one drug that is not listed there in your early-stage pipeline that you are most excited about internally, which is not on the slide.

Fiona Marshall
President of Biomedical Research, Novartis

Oh, well, I mean.

Richard Siegel
Global Head of Immunology, Novartis

Maybe I can mention one that is on the slide, but we haven't talked about, because I think it really is worth talking about, which is the DDY391, the VAV1 molecular glue degrader. That hasn't really been talked about yet today. That's an in-licensed molecule from a small company, Monte Rosa Therapeutics, that are really expert at designing molecular glue degraders. VAV1 is a really interesting molecule that connects T-cell receptor signaling to cytoskeletal rearrangement. It's been a white whale target that, for over 20 years, we and others have been trying to drug, but never successfully, because there are two other homologs, VAV2 and VAV3, that nobody could get specificity, including us. This is an ultra-specific, VAV1-specific molecular glue degrader, which has the potential of being a T-cell receptor signaling modulator, and we're already launched trials in two indications and have plans for more.

We think it could be a biologic and a pill, and a very exciting MOA. That's one of the ones that I think we are most excited about. We did not on the slide or our future bispecific portfolio for AD that we did talk about a little bit.

Fiona Marshall
President of Biomedical Research, Novartis

Okay. Thank you very much. Thank you to the panel, and thank you for all the very informative questions.

Speaker 14

Oh, you're up. Do you have an intern or? Okay. Maybe you could tell him that we switch seats because I think he's going to be going backstage. Good job. Good job.

Patrick Horber
President of International, Novartis

Okay. Good morning, everybody, and welcome to the CRM session. My name is Patrick Horber and I'm the President for International, and I'm joined here by three colleagues. Let me start on the right side by Ruchira Glaser, who is our Development Unit Head for CRM. On my left side, Dianne Auclair Rocha, who is the Therapeutic Area Head for CRM in the U.S. And finally, Shaun Coughlin, who is our Global Head for Biomedical Research as well for CRM. I will start with a couple of introductions. If we look back into 2026, it has been a pretty eventful year for cardiovascular. We have continued to pursue a strategy which is centered, as you know, on three parts, three major pillars, which is ASCVD, it's the one, the second one is cardiac, and the third one is renal.

That with strong commercial momentum, which we are seeing especially on Leqvio. Then as well, key regulatory milestones with the full approval of Fabhalta and IgAN in the United States, and as well the approval of Fabhalta and IgAN in Japan. We had as well a setback on Lp(a), as you all know. We had the data readout of HORIZON a couple of weeks ago. Within ASCVD, LDL-C is still our anchor, and if we look into LDL-C lowering, we see Leqvio continuing to really have a strong growth and strong momentum, and that across all the geographies. Now, even additional supported by the public reimbursement, the NRDL listing in China since January of this year.

We're expecting to have the first data readout of our first outcome trial, ORION-4, as you have heard this morning, and next year, we'll have the data readout of the second one, which is VICTORION-2-PREVENT. Both trials, we will submit to the regulators to get that into the label. For Lp(a), the HORIZON data has been presented at AHA, and we have seen what we have seen in phase II as well, a significant decline on Lp(a) by 78%, but we didn't see a decline on cardiovascular events, which is that what we wanted to see on this outcome trial. We're looking further into the data, and we'll apply the learnings which we have into DII and the rest of the Lp(a) portfolio, and we're not planning to submit pelacarsen.

In inflammation, pacibekitug is on track and will start in 2026 with the phase III trial, and that on post-MI patients, looking into coronary outcome. Finally, on ASCVD, we have hypertension drug, QCZ, which will have a data readout in the first half of next year on the phase IIb trial. As you have heard as well from Vas today, we're looking there to accelerate the opportunity for Asia, as we're very strongly positioned in Japan and in China, still having Entresto in hypertension. Within the renal disease space, Fabhalta is still our anchor drug. As you know, we have a strong performance, which we have shown this year. In addition, we got the two approvals in full approval in the U.S. and approval as well in Japan for IgAN.

In addition, what we can say, it is the only complement inhibitor which has shown significantly slowdown of renal function decline. We didn't see that somewhere else. In IgAN, if we look into our portfolio, as you know, we have three molecules in three different MOAs. Two of them have already been launched in the U.S. and in some of the international geographies, not in all of them. Zigakibart will have the data readout of the pivot study early 2027, which is the BEYOND study. We just started in this quarter the recruitment for the LUMINA trial, a phase IIIb trial, where we're looking into the combination of zigakibart plus Vanrafia to show a potential deepening of the proteinuria reduction and as well remission.

Then if we go into ADPKD, we have farabursen, who could be the first in-class treatment, and that targeting the disease's genetic driver. ADPKD is a disease which is very common. It's the most common inherited kidney disease with almost 12 million patients who suffer from that. Today, we only have one product which is available, which carries a box warning with liver injury. So great potential here. As well here, we started, or we're starting with the phase III program this year. Finally, on atrial fibrillation, we have abelacimab, which is our anchor project, and we're looking there in patients who are unsuitable for oral anticoagulation due to bleeding risk. As you have heard this morning, we had the interim analysis of the LILAC trial, and we're expecting the full data readout in 2027.

We will start in the first quarter next year, 2027, with an additional indication, which will be secondary stroke prevention. Beyond abelacimab, we have a number of assets in development, antiarrhythmic assets with different MOAs, which are rather in earlier development. But we can go then into more details. With that, I would say we go into the Q&A. Let's start here on the right side and then move forward.

Florent Cespedes
Analyst, Oddo BHF

Yes, good morning. Florent Cespedes from Oddo BHF. A question on your QCZ product in hypertension and the, let's say, the long-term treatment and the attractive regimen. Could you share with us how you would like to position the product? Because is it only convenience, or will you use also, will you combine the product with the existing treatments against hypertension? Some color would be great because as cheap products are available in the market today, payers is always a question mark. That would be helpful.

Patrick Horber
President of International, Novartis

Yeah, let me start. I think we'll have to differentiate. One is the acceleration which we want to have for Asia because we see the potential opportunity there. With regard to the rest of the geographies, we will look into the phase II-B, and then we'll make a decision on how we're moving forward there and what kind of patient population. If we go now into the Asian market, or let's say mainly for us, it will be Japan and China, where, as you probably know as well, in Japan, we have the loss of exclusivity of Entresto in 2031. In China, we have entered into VBP, which means we're participating there, and at the same time, we have a PTE over the next four to five years in addition, which means it protects as well our hypertension business to a certain point.

QCZ is a great opportunity as a follow-on of Entresto in hypertension, which probably answers, Dennis, as well, your question. We'll position it in first-line hypertension treatment there. Mainly because we have seen in both countries, or we see that in general in Asia, that the siRNAs have been adopted very quickly. I think the proof as well has been given this year with the launch of Leqvio in China when we got the NRDL reimbursement.

Naresh Chouhan
Founder, Intron Health

Thanks. Naresh Chouhan from Intron Health. Just a question on pacibekitug, please. Given what we've seen with [ziltivekimab and nectemeran] in the past, what have you seen that's different here that gives you confidence to run a phase III?

Patrick Horber
President of International, Novartis

Over to you, Ruchira.

Ruchira Glaser
Development Unit Head of CRM, Novartis

Yeah. So on the ziltivekimab experience in the ZEUS trial in particular, it is certainly an important readout, and that was a negative readout in terms of no treatment effect. That was in a chronic kidney disease population, primarily with atherosclerosis as well. What we observed when we compare those two populations and look at the broader cardio-inflammatory hypothesis are a couple of things. Firstly, the patients where there have been successes in inflammation and coronary artery disease has typically been more with coronary inflammation clinical population. You look at our own experience with CANTOS, with canakinumab, as well as the colchicine data, the successes in those trials were hazard ratios ranging from 0.85 all the way down to 0.69 have been primarily in a post-MI, post-ACS, early first year, onto chronic coronary disease population.

If you compare CANTOS with the ZEUS data, it actually kind of really intriguingly bears out some of those important differences. For example, in CANTOS, only 6% of patients had an eGFR less than 45, whereas in ZEUS, that was 50% of their population. So, a significant difference. If you look at the renal disease itself, the characteristics of the renal disease that these patients had in CANTOS versus in ZEUS is quite different. For example, much more proteinuria, which we know is a sign of significant renal disease. As you would expect in such an advanced renal disease population, the degree of comorbidities was much higher in the ZEUS study compared to CANTOS, which was a more puristic coronary disease population.

I found it intriguing at the AHA when they presented the data on ZEUS and showed that the all-cause mortality rate was quite high in the ZEUS trial. It is double the all-cause mortality rate of CANTOS. The question that asks is the biology where you are trying to address proven biology in coronary inflammation now with an IL-6, are you going into a population that is too severe and has a lot of competing risks and is not the coronary-focused inflammation, but more a pan-inflammatory phenotype? Our strategy for pacibekitug, which is a quarterly subcutaneous drug for IL-6, has always been to build on the previous coronary inflammation successes and to go into a post-ACS, post-MI population, particularly in that first year when we know coronary inflammation is heightened.

We are also building in the learnings from ZEUS to try to optimize the trial's probability of success and treatment benefit even further. For example, we are eliminating eGFR less than 60 from the trial. We are eliminating patients with a history of heart failure, and other things such as that.

Patrick Horber
President of International, Novartis

Thanks, Ruchira. Yes, please. Oh, yeah, that's fine. Okay, then we move on. Sorry.

Graham Parry
Analyst, Citi

Oh, sorry. Graham Parry. Just a follow-up on the abelacimab. Can you just tell us more about what the interim analysis in the trial was, and what would constitute a very high bar? So, what percentage of events was it actually at? Was there futility in there for both efficacy and stroke, the two co-primary endpoints that you had to pass to move forward? What drove the decision to increase the number of patients in LILAC-TIMI 76? Is that what's meant that the trial is now going to read out slightly earlier than the primary completion date on clinicaltrials.gov? Because I think you're saying mid-year, and PCD is at the end of the year. Thanks.

Patrick Horber
President of International, Novartis

Ruchira, would you like to take that?

Ruchira Glaser
Development Unit Head of CRM, Novartis

Yeah. Maybe I'll start with the second question first. You asked about why the increase in the sample size, and you also spoke about the acceleration of the trial, and you're right on that exactly. When we acquired Anthos Therapeutics, we saw that the timelines were somewhat delayed for operational reasons under their guidance in phase III. So in order to have more competitive timelines, we did a couple of things. The first was we massively accelerated the operational engine for the trial to increase the recruitment speed of the trial. The second thing was that we increased the sample size to achieve the target number of events more rapidly. So that strategy has been quite effective, and we now project that the trial would most likely read out in the middle of next year, which is about a six-month acceleration to the previous timeline.

So that is that first question. The second one on the operating characteristics of the interim, as Vas mentioned, we are going to have a design paper coming out in the near future, and that will address some of these questions that you have. What I can say is that we did have both futility analysis and some degree of an efficacy for early stopping for overwhelming efficacy in the interim. But the bar for stopping for efficacy was deliberately quite high. This would be our first registrational trial for this novel therapeutic, relatively small trial on the grand scheme of things. So, in order to have the best registrational package and the best understanding of the data, really quite a bit of demands that were made on the IDMC to stop it that early.

Patrick Horber
President of International, Novartis

Thank you. Go here, and then we move on, and then back.

Steve Scala
Analyst, TD Cowen

Thank you very much. Steve Scala from TD Cowen. So, two questions. First, Novartis should be applauded for pursuing arrhythmia. I am wondering, so you have multiple assets. Are they all targeting the same type of arrhythmia or different? And is there any hint of pro-arrhythmia so far in your assets? That is the first question. Second question is, Vas mentioned a once-yearly, if I heard him correctly, a once-yearly PCSK9 in the morning session. It is not in your pipeline, so I am wondering why. And is this inclisiran just somehow changed, or is this a new molecule? And why are you even pursuing it? I mean, there is so much to do at Novartis. Why is this worth the effort?

Patrick Horber
President of International, Novartis

Let us start maybe with Shaun on the anti-arrhythmic agents.

Shaun Coughlin
Global Head of Biomedical Research of CRM, Novartis

Yeah. We have, as you know, multiple assets in the clinic, including PKN605, which is a HDAC6 inhibitor. They are all directed at atrial fibrillation. We see a big opportunity there. The unmet need is apparent. Only about 20% of patients with AFib receive any attempt at pharmacological rhythm control. There has been very little innovation for decades. We are taking multiple approaches. We have right now three orthogonal mechanisms in the clinic. We hope to have at least one more soon. It is a mixture of completely novel targets and some with better validation, but novel approaches. Do you want to do PCSK9?

Patrick Horber
President of International, Novartis

Maybe the PCSK9?

Ruchira Glaser
Development Unit Head of CRM, Novartis

Yeah, I can manage the clinical rationale and why it has not been on the pipeline. The advantage of the siRNAs is that, especially in established targets, from a development perspective, we can actually use the first-in-human data to model quite reliably with model-informed drug development and dosing what we would expect for the dose. We can sometimes go from first-in-human phase I study straight into phase III for established targets. The reason that FLD170 has not been previously discussed is because it was in the first-in-human space. Now we have those data to hand, and that is why that is on the pipeline chart. In terms of why even pursue it, I think this will play into some of our strategy, particularly for combinations.

If you look at our pipeline and our strategy for atherosclerotic cardiovascular disease, our intent is to cover the full spectrum of the biology that can contribute to cardiovascular risk to eliminate preventable cardiovascular events. Here, because we have that strategy and we have that strength in the siRNA platform and the expertise there, if you can think about durable ways to modify risk over the long run for patients with as few injections or as few therapies as possible from the patient perspective, then that can become a meaningful medicine to patients.

Patrick Horber
President of International, Novartis

Thanks, Ruchira. Please, and then we go there.

James Gordon
Analyst, Barclays

Thank you. James Gordon from Barclays. A question on Zigakibart, so that is your APRIL for IgAN and the BEYOND study that is coming up. What does a good result look like? I think there are competitors, APRIL BAFF molecules that might be more effective and more convenient. Vertex's pove is an APRIL BAFF, and it is monthly versus biweekly, and the efficacy looked pretty strong. When I look at the phase II, Zigakibart didn't look quite as strong. Is that the bar to beat, and do you think you can beat that if you are a bit less convenient, but could you be more effective? Or is it a slightly different population you try and go for?

Patrick Horber
President of International, Novartis

You want to start, Dianne? Maybe from a commercial perspective, and then?

Dianne Auclair Rocha
Therapeutic Area Head of CRM, Novartis

Okay. Yeah. I think from a commercial perspective, we recognize that the anti-APRIL space is going to become more and more competitive. We also recognize that with the KDIGO guidelines, there is broad support that these patients will require multiple mechanisms of action and potentially combination therapy over time. Having all three of these assets, including Zigakibart, really puts us in a unique position to address that patient journey all along. In terms of the data, we have very clear positioning for Fabhalta and Vanrafia. What we are seeing in the market is that we are getting the patients that we are asking for. For Fabhalta, we are asking for patients with persistent proteinuria and glomerular inflammation. For Vanrafia, it is the persistent proteinuria and seamless add-on to supportive care. We will have to wait to see what the Zigakibart data is to determine how we position that.

We have always looked at that portfolio view in the way that we have positioned the earlier products.

Patrick Horber
President of International, Novartis

You want to say something more from a development perspective?

Ruchira Glaser
Development Unit Head of CRM, Novartis

Yes. With regard to the data across the class, it is always tricky to do cross-trial comparisons. That being said, we have in zigakibart a single-arm phase I/II dataset. Those data actually looked quite comparable from a proteinuria reduction perspective to others in the class, and they have held up over time. We have had a 2.5-year experience now, which is the longest running experience with an anti-APRIL, as well as the eGFR. Again, this is not placebo-controlled. However, the eGFR data show slightly positive eGFR for zigakibart. The definitive answer is definitely going to be coming next year with the randomized trial, so I think we will have a better sense of that. When it comes to the dual mechanism, the one observation that I would point out on that is all of these drugs have looked quite comparable from my perspective.

However, the theory or the hypothesis for having a dual mechanism versus a selective anti-APRIL mechanism was the hope that we would see better clinical efficacy with the dual, and so far to date, we just have not seen that.

Patrick Horber
President of International, Novartis

Please.

Sachin Jain
VP, Bank of America

Sachin Jain, Bank of America. Just a couple more on abelacimab, but more focused on the bleed side, if I may. Perhaps you could just kick off with, you say that roughly 40% of the population is intolerant DOACs. Just give us a bit of color as to where that comes from, because our KOL feedback suggests it is more like 10%-15%, but there are patients who bleed on DOACs, so exactly what you are looking at. The second, there was obviously earlier questions on efficacy, but what would be a good bleed outcome from this study, given the background bleed rate is likely much higher than the studies we have seen prior?

And if I can dovetail that into, how do I think about cross-trial comparing this data with what we see from milvexian early next year, given the different comparators and how you plan on positioning it relative to that asset? Thank you.

Patrick Horber
President of International, Novartis

Thank you. Ruchira?

Ruchira Glaser
Development Unit Head of CRM, Novartis

Could you remind me of your first question?

Sachin Jain
VP, Bank of America

The 40%.

Ruchira Glaser
Development Unit Head of CRM, Novartis

Yeah, the 40% comes from real-world datasets, and it combines both patients who are not taking anticoagulants because they are considered ineligible for the standard of care anticoagulants or taking suboptimal doses, which is actually also quite common. My assumption is that the KOLs you have been speaking to are talking about those who are frankly deemed ineligible completely for those. We think that the LILAC dataset, by tackling the hardest and highest-risk population, if proven safe and effective in that population, would actually give you an idea of where you could go in other patients who are now being treated at suboptimal doses as well. So that is the rationale for that number. Your second question had to do with the safety side of what we would expect to see as a meaningful result. There, it is a more complex answer because there is always a benefit-risk equation here.

How much are we actually reducing the stroke risk in these patients in LILAC who are at this point not getting oral anticoagulation and are high risk for stroke, versus is there any increase in bleeding whatsoever? The good news here is that this is a placebo-controlled trial, so we will have a really good idea, even in a high-risk population, both for stroke and for bleeding, exactly what kind of bleeding rates we might see. So it would be quite sensitive trial to understand the characteristics of the drug.

Sachin Jain
VP, Bank of America

Milvexian?

Ruchira Glaser
Development Unit Head of CRM, Novartis

Oh, the read-through to milvexian, in terms of you want to know whether the milvexian data can give us more information or other way around?

Sachin Jain
VP, Bank of America

I mean, milvexian is obviously an [Xa comp], you are a placebo comp. How would you advise us to look at cross trials and how would you position relative to whatever data you see from the competitor?

Ruchira Glaser
Development Unit Head of CRM, Novartis

Yeah. I think for us, the strongest indicator of the potential for abelacimab is going to come from our own LILAC data because it is placebo-controlled, albeit in a very high-risk population. There are biological reasons to hypothesize that we could actually see differentiated clinical efficacy and bleeding profile because this is a monoclonal antibody with a dual mechanism of action. It inhibits both the activated factor XI, which the orals do, but also the inactivated factor XI, which will prevent the formation of activated factor XI. So we could see greater efficacy. In fact, we see 99% inhibition, which is over 30 days, so quite smooth, avoiding the peaks and troughs that can happen, that can create differential efficacy and safety. All of this is theoretical, so we will see, but there is a reason to believe here that we would have a difference to what milvexian would show.

Clearly, if milvexian has good efficacy in its head-to-head trial, then that is a good signal for abelacimab.

Patrick Horber
President of International, Novartis

Maybe just one thing to add more from a commercial perspective. I think, you are in a way asking, do we have a superior product? I think we will have to see. We will have to see based on the knockdown which we are able to get, if we really get a product which is better. At the end, from a commercial perspective, we see a space for us in both scenarios. Clearly, if we have a superior product, it is much better and it will give us probably a much stronger uptake than if we are comparable. Even if we are comparable, there is a market for a once-a-month injectable versus as well oral. So we see that as a huge market, which at the end then will be split between the two.

Simon Baker
Analyst, Rothschild

Thank you. Simon Baker from Rothschild. Two quick ones, if I may. Today we have heard about some of the commercial performances of Leqvio outside the U.S., particularly China. I just wonder if you could give us an update on trends and initiatives within Europe. Then moving on to YMI024, I just wonder if you could give us your thoughts on the potential utility of NLRP3 beyond ASCVD into areas like pericarditis, which may be smaller, but the area of unmet need is pretty high. Thanks so much.

Patrick Horber
President of International, Novartis

Yeah, thank you for the questions. I'll start with the European question which you had with regard to Leqvio. We are seeing a very strong performance across the geographies, as I was saying at the very beginning. Not just China, incredible uptake, Japan as well, and in Europe, especially this year, getting more patients. I definitely believe that with the data readout on the outcome trials, that that will give us an additional boost when we get that in the label. I think one is when the data will be published, it will give more confidence to the doctors. I think that's a bit, I would call it a specialty of European doctors. They like to see the data before they really start to use it broader, even if there is already PCSK9 outcome data there.

Afterwards, more from a promotional perspective, we'll not be able to promote it until it's in the label. There will be a little bit of a delay afterwards. We'll be able, of course, to have interactions with the medical field when the data will be available.

Shaun Coughlin
Global Head of Biomedical Research of CRM, Novartis

I can do NLRP.

Patrick Horber
President of International, Novartis

Yes, please, Shaun.

Shaun Coughlin
Global Head of Biomedical Research of CRM, Novartis

We are excited about the NLRP3 inhibitor mechanism. It will decrease IL-1 production, IL-18 production, and pyroptosis. So it acts upstream and has the potential to hit several of the important pathways in ASCVD and beyond. The potential in pericarditis, I think, is certainly there. IL-1 inhibition works in that setting, and this would be predicted to work as well. I guess the question would be how much opportunity is there, given that the IL-1s do work in that setting. Any crystalline arthropathy ought to be a good bet for this mechanism. Then certainly, many inflammatory states, including CNS, would be on the table for a CNS-penetrant molecule. So it has a lot of potential, a lot of directions to go.

Patrick Horber
President of International, Novartis

Thank you. Peter?

Pete Verdult
Analyst, BNP

Thanks, Peter. BNP. Just two on Leqvio again. Simon asked about Europe, but with the arrival of oral PCSK9, can you remind us what is driving the treatment decision to stay on a monthly? Is it the financial incentive for the doc? Is it the convenience? Is it something else? We can see the trends are strong, but what you are doing differently with the arrival of oral PCSK9? Then look, you have been very candid about the upcoming studies. Do not get your hopes up on ORION-4. Just when it comes to V2P, just a couple of quick clarifications. If ORION-4 is technically a failed study, but V2P is not, can you still pull the data? Can you remind me, and I know I could get this off clinicaltrials.gov, I am being lazy. Can you remind me the relative sizes of each study?

If I could, sorry, I know it is event-driven, but when next year might V2P come in?

Patrick Horber
President of International, Novartis

Let's do first the commercial one.

Dianne Auclair Rocha
Therapeutic Area Head of CRM, Novartis

Okay.

Patrick Horber
President of International, Novartis

Dianne, you can start.

Dianne Auclair Rocha
Therapeutic Area Head of CRM, Novartis

With the orals, first of all, just contextualize where we see the opportunity. We look at this as a There's 30 million patients, and there's still an opportunity for physicians to be prescribing advanced lipid-lowering treatments much more than they do today. Having the orals enter is, we look at it as a positive opportunity to help grow the class share. We only need in the teens for us to meet our forecast. There's more than enough room to go around. What we do see, though, is that the uptake for Lipfendra is not in the same space that we're targeting for Leqvio. We don't expect it to be an immediate threat given their coverage. Today, it's roughly 12%, and you compare that to Repatha, that's over 90%.

They still have a bit of a journey to go before they have that coverage, where the impact will be less for out-of-pocket for patients. Where we have a clear advantage for Leqvio remains in the Medicare population, where the Part B versus the D will deliver much more favorable out-of-pocket costs for patients. We've yet to see an oral show that patients can stay on it. More than 50% of patients drop off orals today after six months. Whereas conversely, we're seeing after 12 months, 80% of patients staying on Leqvio, and we go out now to two years with our real-world evidence.

Patrick Horber
President of International, Novartis

Maybe the only thing which I would add is that I think there will be a significant market expansion for PCSK9s and the injectables, just with the objective to really treat patients as much as you can to target. Because if you think about today, we only have around 30% of patients which are treated to target. I think now they are getting an additional tool of an oral treatment. I am with Dianne. The question is really for how long will the patient stay on an oral, and what will be the adherence and the compliance? Just maybe from an approval perspective, we do not have yet oral PCSK9 launched in international, so they are still in the process of getting the approval.

Ruchira Glaser
Development Unit Head of CRM, Novartis

On ORION-4, I want to remind everyone that the ORION-4 trial is actually quite large. It is over 16,000 patients. The reason for some uncertainty is that when pandemics hit cardiovascular outcomes trials, sometimes the results can be a little bit less predictable. The reason that V2P was begun was to mitigate that, but also the regulatory approval pathway, because the ORION-4 was done in the U.K. and the U.S., and we wanted a more global study that would support the things that Dianne and Patrick are talking about right now across the globe. So V2P is a global study. It also is a very large study. It is over 17,000 patients.

Between the two studies, to your pooling question, you would get quite an ability to pool the data and look for individual endpoints, such as cardiovascular mortality, for example, in a much more robust way than historically we have been able to do. If ORION-4 were completely negative, we would just have to look at the data to understand why that might be, but you can imagine that we would do thorough analyses of both datasets at that point. The poolability tends to come from things like the similarities between the population, where we can combine data rather than what the outcomes are and things like that.

Dianne Auclair Rocha
Therapeutic Area Head of CRM, Novartis

Maybe I will just build on a commercial perspective to this too. For the U.S., to the point that Ruchira made, V2P is the one that we have aligned on with FDA. So we have always anchored our modeling on the availability of the V2P data. So I look at it as a positive if ORION-4 is good, and if it is not what we hope, then we still have V2P, and we have modeled and anchored all the time to V2P anyway.

Pete Verdult
Analyst, BNP

Your best sense when V2P comes, if I can be I am not asking for a date, but just first half, second half next year?

Ruchira Glaser
Development Unit Head of CRM, Novartis

I think it is projected to be around the middle of next year.

Pete Verdult
Analyst, BNP

Okay.

Ruchira Glaser
Development Unit Head of CRM, Novartis

Closer to the second half.

Dianne Auclair Rocha
Therapeutic Area Head of CRM, Novartis

Second half, yeah.

Pete Verdult
Analyst, BNP

Thank you.

Florent Cespedes
Analyst, Oddo BHF

Thank you. Florent Cespedes from Oddo BHF. I will try a follow-up question on Leqvio. I remember when you acquired the product a couple of years ago, I think Vas was quite vocal on your ambition in terms of efficacy of inclisiran versus the existing or first-generation PCSK9 was quite strong, something like 20% plus relative risk reduction of the primary endpoint. Is it something which is still achievable? Because I hear a lot of skepticism and nervousness around the clinical trial readout approaching. That is my first question. And my second question is regarding IL-6. Could you maybe remind us why you are still confident about this pathway, given the other, let's say, mixed or negative clinical trial results from some of your competitors and your experience also with the IL-1? Thank you.

Patrick Horber
President of International, Novartis

Thank you, Florent. You want to cover?

Ruchira Glaser
Development Unit Head of CRM, Novartis

Okay. Yeah. So, your first question. Well, let me start with your second question quickly with IL-6. So, on the IL-6 front, there is good biology and genetics to support IL-6 being an important piece of the inflammatory pathway when it comes to cardiovascular risk. So I think that is the biologic premise for it. Of course, with the ZEUS trial, there is a question mark of, was this the correct population, or is it that we have deviated on the pathway and we do need to be upstream on the pathway? So that still remains an open question. If you look at the clinical data that have been generated that have been positive for the cardio-inflammation space, they have focused on the post-ACS first year or longer, where coronary inflammation is more prominent biology that is happening.

We think with our differentiated trial design that is optimizing, leveraging all of these learnings, where not to go, where to go, that we would have a better probability of success. Still, always when we are going into novel spaces, there is going to be a degree of risk. But on the other side, the reward, if this was a positive study, would be quite significant given the number of patients with atherosclerotic disease and the inflammation not yet being addressed in those patients. Can you remind me the second question? Or the other question?

Patrick Horber
President of International, Novartis

The first question.

Florent Cespedes
Analyst, Oddo BHF

The question about-

Ruchira Glaser
Development Unit Head of CRM, Novartis

Oh, why the skepticism?

Florent Cespedes
Analyst, Oddo BHF

20 + was?

Ruchira Glaser
Development Unit Head of CRM, Novartis

Yeah.

Florent Cespedes
Analyst, Oddo BHF

I think something-

Patrick Horber
President of International, Novartis

You are looking for the commercial ambition. Even not having a 20 plus, if we are able to deliver on the ambition.

Ruchira Glaser
Development Unit Head of CRM, Novartis

Yeah.

Patrick Horber
President of International, Novartis

Is that the question?

Ruchira Glaser
Development Unit Head of CRM, Novartis

Or do we still think we can achieve 20%?

Florent Cespedes
Analyst, Oddo BHF

The question was, is the 20-

Ruchira Glaser
Development Unit Head of CRM, Novartis

Yeah.

Florent Cespedes
Analyst, Oddo BHF

Plus is still achievable?

Ruchira Glaser
Development Unit Head of CRM, Novartis

I think-

Patrick Horber
President of International, Novartis

You mean from a cardiovascular outcome perspective?

Ruchira Glaser
Development Unit Head of CRM, Novartis

Yeah.

Patrick Horber
President of International, Novartis

Okay, sorry. Maybe you can-

Ruchira Glaser
Development Unit Head of CRM, Novartis

Yeah. I think that right now, this is a secondary prevention population. In secondary prevention, the PCSK9's experience, I would point you to FOURIER, for example, for Repatha, where it is more in the mid-teens in terms of treatment effect. We do know that in LDL reduction, the longer you go with these studies, the more treatment benefit you would see. Both ORION-4 and V2P have longer durations of follow-up. I think that plays to our favor when it comes to the magnitude of risk reduction that we could see. That being said, the standard of care continues to improve. We will have to see what exact risk reduction we are going to achieve. I think anything above the mid-teens is going to be highly clinically meaningful to patients in this kind of a disease. I think we will have to see.

I just want to say that the skepticism, I do not want you to misinterpret that we are skeptical about the outcome of these trials. We are very confident in the benefits that Leqvio will bring. The LDL hypothesis is so firmly established as the counterpoint to maybe IL-6, where that is still a novel thing. We know that the more durable, sustained lowering of LDL is translated across multiple studies to MACE benefit. That would be our full expectation.

Dianne Auclair Rocha
Therapeutic Area Head of CRM, Novartis

Yeah.

Ruchira Glaser
Development Unit Head of CRM, Novartis

You might be hearing a little bit of the COVID impact to one of those two trials. That is all.

Dianne Auclair Rocha
Therapeutic Area Head of CRM, Novartis

I will just build on that from a commercial perspective. In the U.S., outcomes are particularly important for guidelines, and you can see that just in the current AHA guidelines set for dyslipidemia, where they have added Leqvio for the first time. For Repatha, they tier the products, and for Repatha, they have given a higher tier because they have outcomes data. They have acknowledged the tier for Leqvio is because we do not have outcomes, but they are expected. So, to Ruchira Glaser's point, anything in the teens and above will be clinically meaningful. Parity still helps us in a guideline positioning, and if we get that differential label, then that is even better.

Patrick Horber
President of International, Novartis

Maybe just to add to this one. I think from an HCP perspective, if they make a decision, what they want to see is an outcome trial. If it is now 15%, 17%, or 20%, I do not think we will get more of tailwinds. I just believe, especially from international perspective, at the moment when we will get the outcome trial and we get it into the label, that definitely will help us to really further master the growth which we are planning to.

Speaker 14

We have five minutes left.

Patrick Horber
President of International, Novartis

Steve.

Steve Scala
Analyst, TD Cowen

Thank you. I have two questions, both on Abelacimab. The first is on the interim look. In my experience, it is quite unusual for a company to proactively call out an upcoming interim unless they are confident it is going to hit. Maybe we can assume it was close. The company has previously said it was going to be taken at 60% of events. Is there another interim, say at 70, 85, or something like that, between now and the conclusion of the abelacimab trial? The second question is, I know nothing about the WATCHMAN device, but I am told that it is a potential competitor to a factor XI. You are an interventionalist. Why would you subject a person to a lifetime of Abelacimab injections when they can get a single device?

Patrick Horber
President of International, Novartis

Ruchira.

Ruchira Glaser
Development Unit Head of CRM, Novartis

Okay. The interim, we had not really disclosed the characteristics of the interim, but I guess you must have heard that it was at 60%. In fact, because you already have that impression, I would say that, in fact, because of the acceleration of recruitments and events, we consolidated the interim to be at a higher number of events. So, it is higher than 60%.

Steve Scala
Analyst, TD Cowen

There is no more?

Ruchira Glaser
Development Unit Head of CRM, Novartis

There is no more because we actually just bypassed that by the time we were able to. So, we did not have to do that 60% interim that he might have mentioned in the past. You are right that typically we would not call out interim analyses. If you take, for example, the HORIZON study or something, these interims are quite different. They are very large-scale cardiovascular outcome studies where, in the interim, you are predominantly setting some futility thresholds, and you have a bar for efficacy that you typically do not expect to be able to meet. In this particular study, the characteristics of the interim, because it is placebo-controlled in patients with such bleeding risk, they are very stringent on both the safety and the efficacy side of things.

I think passing that has given us more confidence, and I realize I'm not sharing with you all the details behind that, but that will be coming to you in a published manuscript soon.

Speaker 14

Last question.

Steve Scala
Analyst, TD Cowen

The WATCHMAN.

Ruchira Glaser
Development Unit Head of CRM, Novartis

Oh, and the WATCHMAN. Yeah, if you talk to certain interventionalists, Eric Topol and others, he'll say, "Oh, you just need a WATCHMAN for everyone." The reality of the situation is that doing invasive procedures is not an accessible reality for most patients, even in the U.S., but certainly across the world. When you think about the fact that in our major markets, the prevalence of atrial fibrillation is 24 million, it's probably not really feasible to put in that many WATCHMANs. There has also been some clinical trials with WATCHMAN that were good, but not as effective as the DOACs in those trials.

That, to me, makes biological sense because while the majority of strokes, embolic strokes that happen in atrial fibrillation come because of the left atrial appendage, which is the area that the WATCHMAN is trying to address, because that is where there is not as much movement, more stasis, it is not everything. A WATCHMAN cannot necessarily address everything.

Patrick Horber
President of International, Novartis

One last question.

Speaker 14

Do not make it really short.

Patrick Horber
President of International, Novartis

The answer will be short if the question is too long now.

Sachin Jain
VP, Bank of America

Abela SSP, as you think about starting that study, are you going to wait for the milvexian details before deciding baselines? If not, you are shaking your head, what is your view on index window and lacunar infarct?

Ruchira Glaser
Development Unit Head of CRM, Novartis

Yeah, we are not going to wait on the milvexian data to start the study. Good news is that just because it takes time to recruit studies, it will naturally fall that we will get the data, the full data set at some point earlier in our trial. We certainly will look at the data, and if we see surprises, we will learn from the data and be able to still adjust our own trial.

When it comes to the windows that you are talking about, yes, in the asundexian data set, there seemed to be this intriguing signal that if you go later in the window from 0- 72 hours, you see more efficacy. I would just be cautious that the 0- 24 hour window in that trial was so small. It is like in the hundreds of patients per arm versus in the thousands of patients per arm.

There could be noise on that, and we will get a better idea with milvexian. Milvexian is looking from 0- 48 hours, so you will get more patients sort of in both windows. If you talk to neurologists, there is not really a paradigm at this point clinically that you would wait on somebody who is having a stroke to give them anticoagulation and give them that protection. So it would probably be a pretty high bar to cross to really be able to mechanistically support that giving, delaying treatment for patients is a good idea.

Sachin Jain
VP, Bank of America

Stroke subtype?

Ruchira Glaser
Development Unit Head of CRM, Novartis

Stroke subtype, yeah. There has been some, I do not know if you are talking about the lacunar strokes and the enrichment for atherosclerosis there that Bayer did. Hard to know because that was the inclusion criterion, that the majority of patients obviously that had lacunar strokes had concomitant atherosclerosis. It was a pretty broad atherosclerosis inclusion, so did not really have to show much.

But interestingly, even though it is a small data set, they did do a subgroup analysis for people who did not have demonstrable athero versus people who did, and there was no difference in the point estimate there. So I think unlikely that that degree of complexity is going to pan out to be anything helpful. Obviously, milvexian, we will see, but it is going to be hard to know because there are so many other things in milvexian, which is the thing that makes the difference. Yeah.

Patrick Horber
President of International, Novartis

Thank you, Ruchira. Thanks a lot for your attention.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

I am Shreeram Aradhye. I am the Head of Development and the Chief Medical Officer of Novartis. Joining me today are Shiva Malek, Head of Biomedical Research for Oncology, Andrea Myers, Head of Development for Oncology, and Reshema Kemps-Polanco, our Chief Commercial Officer in the U.S. with a long previous life in oncology. As you heard this morning, our overall strategy in oncology remains constant. We remain focused on bringing Scemblix, Pluvicto, and Kisqali to all the patients that can benefit from them. Our key focus areas in terms of tumors remain breast and prostate with an increased continued interest in hematology.

RLTs as a platform remain a big area in which we have built significant capabilities across the entire continuum. We look forward to continue to bring actinium-based PSMA therapies, and then behind it, a number of potential opportunities for identifying both new targets, potential ligands, and isotopes to then figure out which combination offers us a differentiated therapeutic index to turn into a potential option for patients. With that, I look forward to answering your questions with my colleagues. Florent?

Florent Cespedes
Analyst, Oddo BHF

Thank you very much. Good afternoon. Florent Cespedes from Oddo BHF. Maybe two quick questions regarding two assets you have in breast cancer. The CDK2 product, how could be differentiated versus the existing treatments? Same question for the pan-mutant selective PI3 kinase. We discussed that last night during the dinner. If you could come back on

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

Shiva, why don't we start?

Shiva Malek
Head of Biomedical Research of Oncology, Novartis

All right.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

Shiva, why don't we start with you, and then you can move on to the others.

Shiva Malek
Head of Biomedical Research of Oncology, Novartis

Yes. I am happy to tell you about our CDK portfolio. Our CDK2 inhibitor, ECI830, which is currently in phase I clinical studies, is a homegrown molecule designed specifically to be as selective as possible for CDK2 and spare CDK1. We are close to almost 200-fold selectivity window between those, and we thought about how we can spare, especially heme toxicity with the CDK2 inhibitor because we know the clinical plan is to combine it with CDK4/6, with Kisqali, of course, CDK4 inhibitors, and other endocrine therapy. So, really optimizing preclinically on the safety profile, and we will see how that plays out clinically. On the pan PI3K mutant selective molecule, this molecule was acquired through Synnovation. Very exciting profile.

This molecule is both kinase domain mutant as well as helical domain mutant selective, and we believe both with the way this molecule binds to mutant PI3K as well as its ADME-PK properties, we can get optimal target coverage for both kinase and helical domain. Now, I will add that, as you know, we have extensive experience in drugging PI3K, of course, with our experience with alpelisib. So, we had a lot of insights and learnings from the clinical data that we had, understanding exactly what exposures drove, say, the hyperglycemia, so how the component of wild-type PI3K inhibition, as well as what is required for efficacy for the mutant PI3K. It was really that insight that informed us on the exact profile of the molecule we need, and we believe that the Synnovation, this PI3K inhibitor, meets all that criteria.

Maybe I will hand it over to Andrea to tell you more.

Andrea Myers
Head of Development of Oncology, Novartis

I will kind of weigh in on both of those. I think we have a really rich experience with Kisqali, preclinically, translationally, and clinically, right? All of those learnings have really informed what we want to bring forward in our CDK pipeline. So I think Shiva noted the CDK2, but we know we have a good sense of what good looks like and how we want to be able to combine it with standard of care, including Kisqali and estrogen therapy in hormone-positive breast cancer. With regard to our asset list innovation, PI3 kinase pathway is a critical node in treating hormone-positive breast cancer. 40% of patients have PI3 kinase mutations, and as we noted, they fall in two different places, right? This helical domain and the kinase domain. Actually, they have different scientific downstream implications, but hitting both of them is critical.

We have experience collectively with a lot of PI3 kinase inhibitors, and they fundamentally show efficacy, but still, we really need to get better on the tolerability. If you can nail the PI3 kinase signaling in the tumor and relieve in the rest of the body, this is what a winning medicine looks like to totally deliver on efficacy with managing tolerability, allowing additional combinations of standard of care. We knew exactly what we were looking for when we were looking for a pan-selective mutant inhibitor, and we think we found it.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

Okay. Matthew. Graham.

Graham Parry
Analyst, Citi

Thanks. Graham Parry from Citi. One, just follow-up actually on CDK. CDK4, we've now seen some pivotal data in a late-line setting. I think you're still only pre-clinical on CDK4, so perhaps just talk to how you see that going forward and why sort of continue, I guess, with the Kisqali CDK2 combination? Why not just sort of reprioritize into CDK4? What are the timelines to market for that? Then I've got a question on the Pluvicto and radioligand therapies. On the Q3 call, I think Vas said that the proposed NRC guidelines for patients discharge in terms of the amount of radioactivity they can sort of give to their loved ones. There's a draft which has been proposed which is much more restrictive, and that could cause problems for some of the centers.

The comment, I think, at the call was that we're not seeing any behavior on the back of that at the moment. Of course, that's just a draft guideline. Could you perhaps just update us on your expectations for when we'd get the final guidelines and what the scenarios might be, particularly for sort of the community centers who are starting to try and become radioligand treatment centers? Thank you.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

Reshema, do you want to take the Pluvicto one first and-

Reshema Kemps-Polanco
Chief Commercial Officer, Novartis

Sure. I can do this quickly. I would not have much more to add since the call, which was just a couple of weeks ago on that one, so we will have to see. Right now, we are not building in any type of, I would say, suppression in the community setting due to this at the moment, but I think we have to see how it plays out. For now, we continue to have the expectations that we have had and uptake in the community, which I can talk more about because I am sure there will be questions about. Our RLT and I can address what we are seeing now and what we expect in the future. Why do I let you take on the CDK4 versus two?

Shiva Malek
Head of Biomedical Research of Oncology, Novartis

Right. Maybe I can first start by saying, so what we have done is we have built a portfolio of CDK molecules. You can see behind ECI830 is GVV858 and IEV407. These molecules we have optimized based on what we think is the necessary selectivity profile to hit four, to hit two, to get maximal cell cycle arrest. That is the strategy. Those molecules are also in phase I, and we are going to see how the early clinical studies play out and what both the safety and efficacy profiles look like and advance the best combinations for patients. Andrea, do you want to-

Andrea Myers
Head of Development of Oncology, Novartis

Yeah.

Shiva Malek
Head of Biomedical Research of Oncology, Novartis

Address the clinical plans?

Andrea Myers
Head of Development of Oncology, Novartis

Yeah. I would offer again, Kisqali actually has the most potency against CDK4 of the four or six inhibitors. Again, we have a great sense of exactly what we're looking for as we bring this next class of medicines forward. With those targets, we really want to make sure we're getting tumor specificity and potency on the right CDKs and not on the rest. We really see an opportunity for enhanced potency, but also tolerability over the long time. As noted, as we get that early experience with our pipeline now, we have three in the clinic, two more to come, that we really will be capitalizing on our experience from Kisqali, looking at the data quickly to make some of those early decisions. Yeah.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

What you see, Graham, is that this to me is a good example of how building on the competencies that we have built over a long time in the space, this is about creating optionality. It's fully recognized that exactly where each of those specific molecules could play will depend upon both what profiles emerge as well as how the competitive space and standard of care evolves. I think that perhaps compared to sometimes in the past, our new ways of working, we're having decided that this is an area that we focus on, and making sure that we're making the early investments, learning from everything we have, including in tech-enabled manners, as Vas pointed out this morning, from those learning loops around CDK biology and our understanding of all the molecules that we have worked with to ensure that we are creating a rich set of options.

To be determined how they will progress, including what type of clinical development plans, which ones we'll take forward or not. But we see real value in having that optionality.

James Gordon
Analyst, Barclays

Thank you. James Gordon from Barclays. For Pela, I heard some excitement about the European opportunity, but in terms of the path to market in the U.S., is it definitive that you can't get approved on the existing data? What would be the different routes you could get a U.S. approval, and would you definitely do that? Would it be worth running all those trials? How much IP is left on it, and could it be complicated if you priced it for one level in Europe, but then you do get it to work in the U.S.?

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

I think, well, I think the pelabresib story at this point is that, as you recall, the MANIFEST-2 data and how it evolved over 96 weeks, and then the longer term 144-week data, over time, the benefits on spleen volume reduction was maintained, the benefit on symptoms was maintained. Some of the concerns around the side effects actually got moderated over time. We are seeing numerical differences in deaths. We are seeing evidence of disease modification. It was that overall package and the response from the European regulators that gave us the confidence to submit on the basis of MANIFEST-2 in Europe. With the FDA, we have taken the opportunity to have the conversation about, based on what we are seeing with MANIFEST-3 having already been designed and running and with a lot of enthusiasm from the community for both participating and wanting access to pelabresib.

What we are in active discussions about is whether there is an opportunity on the back of MANIFEST-2 to bring the drug to U.S. patients on an earlier basis using accelerated approval. That conversation is currently active, but if not, then it's MANIFEST-3 that'll serve the basis of the filing in the U.S.

James Gordon
Analyst, Barclays

Thanks.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

Steve.

Steve Scala
Analyst, TD Cowen

Thank you. Steve Scala from TD Cowen. I'd like to ask a question about Novartis's defense of Kisqali against approval of giredestrant in the adjuvant setting. You were asked this question on the third quarter call, and Vas responded by saying, "Well, we have longer-term data. We have OS data. By the way, the mechanisms are different, but it's pretty subtle." I'm struggling with his answer because this all seems to me to be very similar to Novartis' playbook in the CDK4 space against Lilly, which worked wonderfully well, and actually is very similar to Novartis' argument in PCSK9. We don't have all that stuff. We don't have longer-term data. We don't have OS, but trust us. Why can't Roche say the same thing and lead to a real difficult future for Kisqali?

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

Shiva, why don't you-

Shiva Malek
Head of Biomedical Research of Oncology, Novartis

No, so you.

Reshema Kemps-Polanco
Chief Commercial Officer, Novartis

I appreciate the challenge. Let me take a moment to step through it. The first thing I will say is we remain confident in the $10 billion peak sales guidance. The thesis behind that is, one, this is the number one CDK4/6 across metastatic, early breast cancer, regardless of combination partner, right? Strong reimbursement, 99% reimbursement, right? Market access matters, as well as NCCN guidelines, which are very strong. You could say we're an entrenched competitor for anyone who's coming in, and you've also heard us say the opposite. When we're going into a space, we also say it will take some time to dislodge that entrenched competitor. In this case, we are they.

One of the things that is instructive about what we have learned in metastatic disease, where Kisqali continues to be the market leader in first-line metastatic breast cancer, if you look at where the oral SERDs are, they are pretty much relegated to ESR1 mutant, the population. That will be a red ocean for share capture. It has been mixed in metastatic, right? One of the things that drove the success of the CDK4/6 class in early breast cancer is extensive experience in the metastatic space for years across multiple products and multiple companies. That will not necessarily be the case and something that will have to be mitigated, because if you look at the time horizon for which these therapies are going into both metastatic and early breast cancer, that is not necessarily the case.

The majority of the physicians who are writing at early breast cancers were the ones who started writing in the academic centers in the community in metastatic breast cancer. I think that is an important distinction. Market access is another important distinction. If I go now to the early breast cancer space in terms of the entrenchment proof point, we have over 60% share overall, 68% share in our exclusive population, and 56% share in the overlapping population within the CDK4/6 class. Now, let us put the oral SERDs in the place where they are really going to try to contest, right? If you think about the high-risk patient, I think that is going to be a hard place for them to contest use because dual inhibition is clearly the standard of care. Those patients need greater intensification.

If you then take the lower end of the disease where CDK4/6s are not indicated, perhaps, and that will be probably the first job for them to do, is to say, "Hey, let us become the replacement for ET monotherapy." That is not a place where intensification is indicated. Then where is the true space where there will be the contest? In the stage two population, right? There, where Vas was speaking to, it is not a question of, is it a CDK4/6 versus an oral SERD? It is about approach to treating the disease. Do you continue with hormonal therapy? Although maybe this is perhaps a better one, but it is still monotherapy. Or do you go for dual inhibition because these patients require intensification?

Shiva can speak just in a moment, like what that means scientifically, because I think that is important for patients and physicians to understand, and also all of you. Then, if that woman is sitting in front of a physician, she has been through a lot. I just want to make it real. She has been through surgery, she has been through perhaps chemo, perhaps radiation, and now she is going to go on this treatment. Now, what we see with the NATALEE six year follow-up is that the benefit continues to widen off of treatment. There is a durability argument to be made there that the oral SERD cannot yet make because it is just too immature. For the choice, I would say for the near term, I still believe will break towards the dual inhibition.

Kisqali is the number one CDK4/6 because we continue to see the benefit. Here we are talking about a cancer that can come back in three years, five years, 20 years later. Once a patient understands that, if they have got to go through this, they are going to want to get the best shot they possibly can to prevent this from coming back, because they have already been through hell. For those reasons, we feel very strongly that we will have been able to hit the peak sales on this, and we will be able to defend the franchise. Shiva, I would love for you to speak to the dual inhibition.

Shiva Malek
Head of Biomedical Research of Oncology, Novartis

Yeah. Maybe I will just add, from a mechanistic standpoint, estrogen signaling does regulate cyclin D1 expression. So endocrine therapy, whether it is SERDs or other approaches to it, will drive down expression of cyclin D1, but there is residual cyclin D1 left, which is why you have to come in with a CDK4/6 inhibitor, which cyclin D1 binds to and activates, to really strongly suppress the cell cycle. That is basically the way by which we stop the tumor cells from growing. The complementary pathways that we just talked about, for example, CDK2 inhibition, is another way to really bolster that. So it is really two complementary and converging mechanisms, but they are distinct still. They are not the same.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

I think, I mean, we have seen, I think for me, the idea that, and Andrea Myers is a breast oncologist, that we have now a well-established practice where dual inhibition is the best means of preventing recurrence in this cancer, becomes a well-entrenched way of treating patients. The fact that a better hormonal therapy becomes available and where it gets introduced is for that pillar of therapy, but not so much a decision on whether, because it is a better hormonal therapy, I do not need to use CDK4/6 inhibition. That is where we are coming from. Sachin Jain? Sorry. Oh, Holger Blum, you have it. No, go ahead. You have the mic.

Speaker 13

Okay. Thank you. Holger Blum from [Bellevue Asset Management.] My question is on bispecifics. In immunology, you indicated you can break through efficacy ceilings, and in oncology, it is probably even more common to fortify existing mechanisms as a bispecific. So how do you look at the space, and do you see a chance maybe to revive a target that has miserably failed as monoclonal antibodies, like CD47, and revive that as a bispecific idea? What is your effort, and what happened over the last year in this respect?

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

Shiva, do you want to start?

Shiva Malek
Head of Biomedical Research of Oncology, Novartis

Yes. So, yes, we are very interested in harnessing the immune system to tackle both heme malignancies as well as the solid tumor setting. We are working very closely with the immunology team, both in the B-cell reset setting, thinking about using bispecifics, but also different approaches, for example, mRNA-based delivery of the T-cell engager, which was the Abogen deal that we recently signed, which has the potential to mitigate some of the acute toxicities that we typically see with T-cell engagers. We definitely are very interested in expanding our expertise and our insights into the solid tumor space, particularly by adding additional mechanisms, for example, co-stimulation. So the PIT565 molecule that Vas described this morning, that is a trispecific that we developed together with immunology to enhance the activity of the T cells. And those are approaches we are very interested in implementing in the solid tumor setting.

Yes, I agree. I think it is interesting to revisit some of the targets that have been clinically validated with an approach that we think will boost efficacy.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

All right. Sachin?

Sachin Jain
VP, Bank of America

Sachin Jain, Bank of America. Can I take a few more follow-ups on the Kisqali, giredestrant, if I may? I have three questions. One, Roche are pretty vocal on using a coupon program, so do you need to do anything commercially to offset that through 1H? Obviously, you know, here is a drug for free versus please pay me $200,000. Two, your answer has focused a lot on efficacy, which I totally understand. Part of their pitch to me, it seems to be safety, so ECG monitoring and that 50% of patients discontinue CDK4/6. Given that a lot of adjuvant patients are in the community setting, just interested in your perspective on that. The last question, obviously, these questions are very focused on the U.S. Decent part of your business is ex-U.S.

It seems to me they cannot file for quite a long time until they have got mature OS. Any best guess when you think the ex-U.S. competition comes? Thank you.

Reshema Kemps-Polanco
Chief Commercial Officer, Novartis

Yes. When you look at the impact of a coupon, it depends on what we are talking about. If we are talking about a free trial program voucher, remember, you are not able to use those in the Medicare setting, where the government is reimbursing. What we know is that a significant portion of these patients, we know from the real-world data, are in the Medicare segment in terms of being older. With that said, where you have these free goods programs come in is when you have an access challenge. For us, it is 99% access. I said in the other session, it is like 99.9%, like it is close to 100% as you can get. There is not an issue in patients obtaining Kisqali. I am wondering, are they doing that because they anticipate market access challenges?

That is a question you would have to ask them about. I do think that will be a limitation when you look at the government segment versus commercial patients. On the piece around discontinuations, if you are talking about the overall CDK4/6 class, again, all CDK4/6s are not created the same. I think we know that, and the differences between our medicine and the current competitor. If you are thinking specifically to Kisqali, I would juxtapose that to what we are seeing, is that our persistence continues to grow and has not hit its cap. In fact, I was just telling the team the other day, we were having a performance review, and I was asking them, where do they think the theoretical max is, the ceiling on persistency? It continues to grow, and it has looked really good.

I am not seeing a significant difference versus what we have seen in the clinical trial, but that is Kisqali. If you are talking about all CDK4/6s, then you would have to take into the fact the tolerability profile of perhaps other CDK4/6s that are approved. Then ex-U.S.?

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

Yeah.

Reshema Kemps-Polanco
Chief Commercial Officer, Novartis

I cannot speak to when they might file. I mean, I think that would be inappropriate for me to try to speculate when they may file, but I think you are right, there is a gap there.

Pete Verdult
Analyst, BNP

Thanks, Pete at BNP. Just one question, and before I ask it, I want to just call out, you guys are crushing it on Scemblix. But if we take a long-term view, you have done a great job with the mouse trap, improving the mouse trap each time. But when we think about the CML pipeline going forward, are there any assets or thoughts that you have in terms of what is next? I suppose I am asking the question because you have done a great job with the iterations in CML, but you have now got competitors trying to do the same thing, Merck buying Terns. So your thoughts on long-term competition and the CML pipeline at Novartis beyond Scemblix?

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

I will start, then I will ask Shiva to comment. I think we are delighted at how Scemblix is performing, and we believe it is a direct reflection of the very key insight that led to the identification of the pocket and then the creation of asciminib. We are super happy about it. It is very clear that all the expectations on how people will adopt it into first line have been exceeded, and things are getting better and better. We fully expect that as time goes by, our focus now is on generating all the data we can with Scemblix, including generating the data that tells you about eligibility for treatment-free remission.

All of that data is coming in. As we think about how the space is going to go further, we realize that a large number of patients, as they move through this treatment, are going to have likely been treated with Scemblix as their first-line option. It is in that context that we evaluate everybody else's plans. Our own, Shiva, let me have you comment on it.

Shiva Malek
Head of Biomedical Research of Oncology, Novartis

Yeah. I will have to say the story of Scemblix and how it was developed in-house from basically a silent binder from a fragment screen to the molecule that you see today is incredible. It is one of the reasons I came to Novartis because of that innovation. I would say Scemblix is a great medicine. We know that we are able to achieve really great target coverage in both the front line and second line setting. We only see about patients that progress on Scemblix, there is only 4%-8% of them that actually have ABL mutations. That speaks to how strongly you are covering the target. As we go back to research and ask ourselves, "Where can we innovate next?" Our focus internally is going to be on the next breakthrough innovation.

We really think about how can we achieve deeper molecular responses, treatment-free remission, and how can we target the leukemic stem cell compartment that also expresses BCR-ABL. We are thinking about really how to innovate beyond just your traditional kinase inhibitor or STAMP inhibitor. There is a lot of work currently ongoing in-house. Again, based on what we have learned with Scemblix, we know exactly the exposures that are required to get deep inhibition of the pathway and the profile that we need with a next-gen molecule to really have significant impact. Hopefully we will share that in the next few years as the programs progress.

Reshema Kemps-Polanco
Chief Commercial Officer, Novartis

Yeah. Maybe I can just follow up because you mentioned the incoming competitor. We believe there continues to be quite a bit of headroom, and that is why you see the guidance going up on Scemblix. For those of you who attended ASCO, when we gave that presentation, I said the number one barrier we had to cross then was the market access barrier because we were launching a new medicine, which we knew was differentiated, but we are still launching it against the background of genericization. We did, so we have cleared that hurdle. Now we see in the front line setting, hitting that 33%, now becoming a market leader in the front line setting, we still believe there is headroom to go.

And with the head start that we have ahead of the competitor, we also know that there is a long duration of therapy in the CML space. If you look at just imatinib, it is one of the best when you think about persistency, it is one of the best analogs. I think the bar is really high for any competitor coming in. We are kind of on to the next question, which is, what the team has been discussing is, can you get now into the Scemblix, the medicine, where you can actually demonstrate treatment-free remission for patients in a meaningful way?

I think the other competitors are probably, they are going to be coming in the back end of the disease, but it will be a while before you can get to that, answering that question, that is really the next hill to climb for us. Do you want to think about that?

Shiva Malek
Head of Biomedical Research of Oncology, Novartis

No, I mean, I would add, look, we have really continued to build, right, from imatinib to the second generation and now to Scemblix. This is no longer a clinical sprint. This is a marathon when you think about how to manage a CML patient, I think the 144-week data of Scemblix, it is about efficacy and tolerability together, right, keeping patients on to get the benefit of that drug. That is where the success of Scemblix clinically really plays out.

Simon Baker
Analyst, Rothschild

Thank you. Simon Baker from Rothschild. Two questions, please. Moving on to actinium PSMA. Our discussions with players in the industry suggest that the supply chain on actinium has improved massively since the raised buyer problems a few years ago. It would be interesting to get your perspectives on eased and quantity of supply. Then a slightly broader question on modalities. A few years ago, there was a tremendous buzz about targeted protein degradation. You were probably one of the first to make a lot of noise about it. It seems to have gone a bit quiet more recently. So just your updated thoughts on the potential of that modality would be great. Thank you.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

Shiva, I'll get the TPD question to you, but on actinium supply, I'll just say that you heard Steffen speak about it this morning, that we recognize the importance of having a reliable supply chain. We are ahead on our phase III studies and how they're reading out and are taking the necessary steps to be able to secure the necessary supplies for being able to meet the needs as we forecast them at the present time. Reshema, anything to add on that, or I think we're okay on that.

Reshema Kemps-Polanco
Chief Commercial Officer, Novartis

No.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

Yeah.

Shiva Malek
Head of Biomedical Research of Oncology, Novartis

Yeah, so-

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

The targeted tool.

Shiva Malek
Head of Biomedical Research of Oncology, Novartis

Yeah, so I would say I remain very excited about the targeted protein degradation and now expanding it into the induced proximity space. In fact, I'm heading to EORTC tomorrow to chair that session. We remain very excited about it, and we continue to have programs in clinical development, including an AR degrader, that's a heterobifunctional degrader that's currently in phase I/II studies, and a lot of work coming behind that. I think the key question is, we start with disease first. Disease, think about what we're trying to achieve in patients in that disease, given the setting, the standard of care, and then what is the foundational target that needs to be drugged there, and then match that to the right modality. We're not really leading with modality first. It's first, what are we trying to impact in the disease setting for patients?

Where it makes sense, I think targeted protein degradation can have profound effects. You can get this catalytic mechanism, get very deep suppression of the pathway. There are other ways that you could leverage degradation through non-catalytic mechanisms that that target may have. Then, of course, this has helped us build an induced proximity platform as well, because, of course, a lot of the chemistry is similar, and trying to leverage other ways to induce cell death in a tumor-specific way. So there still remains a lot of potential. We are very much invested in it, both in heterobifunctionals as well as molecular glues, and continue to advance that early portfolio.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

I think we just stopped talking about it because it has become part of-

Shiva Malek
Head of Biomedical Research of Oncology, Novartis

It is part of our-

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

It is part of a toolbox-

Shiva Malek
Head of Biomedical Research of Oncology, Novartis

Exactly.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

That just allows you to do the decision.

Andrea Myers
Head of Development of Oncology, Novartis

I would also just note, I mean, luxdegalutamide is a PROTAC, it's a heterobifunctional degrader to AR, what's in phase I/II studies. We've taken a slightly different approach, not with regard to monotherapy, but actually looking for combinations based on two mechanisms of action. Number one, how it degrades AR and reduces the signaling. It also has a secondary mechanism action of increasing PSMA expression, right? So we have two combination programs that we're looking at with luxdegalutamide, including a combination with Pluvicto, as well as a combination with abiraterone to kind of have that enhanced AR suppression. Again, a biology we're excited about.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

Cool. Steve?

Steve Scala
Analyst, TD Cowen

Thank you. A couple questions. First, Scemblix received accelerated approval in frontline based on MMR. Any reason why Merck can't do the same thing and come to market more quickly? Secondly, if Pfizer's mevrometostat were to fail in phase III, and we should know that pretty soon, how would you think about your own asset? I guess the easy answer is you'd want to see the data, but any thoughts would be helpful.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

Go ahead, Andrea.

Andrea Myers
Head of Development of Oncology, Novartis

Yes, I will take the second one first. Yes, we have an EZH1/2 inhibitor, tulmimetostat. We selected this based on some preclinical data. We see a higher tumor retention, so we think there is opportunity there of a biologic or a kind of chemical distinction from the Pfizer asset. They have also see opportunities potentially with other differentiation. We have two studies that we are kind of moving forward there in combination with different RLTs to try and understand the opportunity there. We also have it in combination with luxdegalutamide, seeing an opportunity there. Again, the hypothesis being with an EZH1/2 inhibitor that you are kind of prolonging the dependence on androgen receptors, and that is fundamentally what is informing those studies.

These studies are actively enrolling, so I think we will have the chance to look at the data, and hopefully we will make the decision on our own data, not necessarily on what Pfizer reports.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

On the Scemblix accelerated approval, do you have a perspective, Andrea?

Andrea Myers
Head of Development of Oncology, Novartis

Do I have a perspective? I mean, it's-

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

On the Merck-

Andrea Myers
Head of Development of Oncology, Novartis

I think it's a little bit hard to say. Indeed, that is how we got our accelerated approval. I think, beyond approval, this duration of treatment with Scemblix, that long-term efficacy and tolerability is the real win in frontline. I think it's hard to speculate what the FDA might do, but when it comes to uptake, we really have a nice drug in Scemblix.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

Steve, I'll just say that what we've certainly learned over the past few years now is that when it comes to accelerated approval, meeting the basic need that you need to be able to bring something that's not currently available or to patients where a true unmet need exists as the basis of accelerated approval is a principle that doesn't get violated. I mean, we've seen that.

Andrea Myers
Head of Development of Oncology, Novartis

Yeah.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

Graham?

Graham Parry
Analyst, Citi

Thanks. I have two questions on Kisqali. For the six-year overall survival data, the trial wasn't actually powered for superiority on OS. I think the Verzenio study was. How do you expect that data to get reflected on the label in terms of overall survival, and does that give you any kind of competitive uptick against Verzenio, particularly in that high-risk patient population where it tends to do better? Secondly, just on the, going back to the giredestrant debate on the impact there. I mean, I think Roche's data suggests that in that intermediate-risk patient population, CDK 4/6 is only about 20% penetrated, and even in high risk, it's only about 50% penetrated. So there's a lot of endocrine monotherapy patients out there that's probably more their target. Is that your assessment?

Do you think there's a difference there between the KOL community and then community centers in terms of usage of CDK 4/6? Is it more in the KOL community that you're seeing CDK 4/6 and actually less in the community? That's, again, perhaps more where the monotherapy SERDs would go. Thank you.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

Reshema, do you want to talk about how the OS data will play out in the U.S. label and-

Reshema Kemps-Polanco
Chief Commercial Officer, Novartis

Yes. We're already seeing it play out early on in terms of reassuring physicians of the long-term benefit, and again, that widening improvement off treatment. I think it just reassures about the class, right? Because now you're seeing it across CDK 4/6s. Now, the question is, which is the best CDK 4/6 when you take the totality of the data into it? I think we'll continue to see, going on to your next question, we'll continue to see uptake of CDK 4/6 growth in that N0 and N1 population. In fact, we continue to see those numbers rise in the exclusive population with the share obviously breaking towards Kisqali. We are seeing community is driving a lot of this, because that was one of the first thesis. When you start to go earlier in disease, you're automatically in the community.

When the community has had, again, I'll go back and say it again, when they've had a lot of experience in a later stage of the disease, I believe if I go back and think about it, the same was true for, we're seeing in prostate cancer and CML, those 70%-80% of those doctors end up riding earlier in disease. I think that's, again, going to be an interesting thing to see the oral SERD try to truncate that time and create that experience for uptake. Anything you would add?

Andrea Myers
Head of Development of Oncology, Novartis

I mean, I might add kind of the characteristics, right, of that OS curve, right? It's just really satisfying to see that consistency and depth, and narrowing over time. This is certainly what we're hearing from our KOLs, as well as framed with an increase in the invasive disease-free survival delta now at +5.3. So, the curve is there.

Graham Parry
Analyst, Citi

That speaks for itself.

Andrea Myers
Head of Development of Oncology, Novartis

Yeah.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

Yeah. All right. Steve?

Steve Scala
Analyst, TD Cowen

Two questions, I apologize if they've already been asked. What is the opportunity for in vivo CAR T when we have in vivo CAR T? Is there an opportunity still? Secondly, you have a very early stage B7-H3 ADC, lots of competition, and many are later stage than Novartis. Why are you pursuing this?

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

Shiva, do you want to start?

Shiva Malek
Head of Biomedical Research of Oncology, Novartis

Yeah. Maybe let's start first by in vivo CAR T. I think the hope and promise of in vivo CAR T is to mitigate the complexity that is involved in autologous CAR T, right? Both from manufacturing complexity, the time it takes to deliver to patients, and the cost. The question is, and we see early signs of efficacy, the question is around durability, safety, both near-term as well as long-term safety, and then the manufacturability and scalability of such approaches. We're taking very much an informed approach on this. We have an existing external partnership. We're very interested in advancing in vivo CAR T, but we think it's important to go into this kind of eyes wide open and learn from what others have reported and really dial in on both efficacy, but safety, and build a manufacturing platform that is sustainable.

That's the in vivo CAR T space. I still think very excited about it. Second question was around

Reshema Kemps-Polanco
Chief Commercial Officer, Novartis

B7-H3, yeah. B7-H3.

Shiva Malek
Head of Biomedical Research of Oncology, Novartis

Oh, B7-H3. Oh, that is related to the acquisition of Myricx Bio. We acquired Myricx Bio in July of this year, and the reason we were very interested in their technology platform, they are developing a novel set of payloads that targets N-myristoyltransferase. This payload class is quite different from the Topo and MMAE-based payloads that we see other B7-H3 ADCs being advanced. We believe both the safety and efficacy profile of these molecules will be different. As we were looking at what novel and differentiated payloads were available to us, and of course, we are working on this internally as well, we were really interested in payloads that had the potential to go into multiple solid tumor and potentially heme indications, but a payload that would have a differential safety profile, which we believe NMT will, and also that was not cross-resistant to your Topo or MMAEs.

We are able to study this ADC in patients that have had prior Topo or MMAE-based treatment and really understand the risk-benefit profile and then take decisions on that, and how we will advance it.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

All right. Last question.

Naresh Chouhan
Founder, Intron Health

Just back to the ER-positive adjuvant setting. What percentage of patients are on endocrine therapy mono that are intermediate patients, and is that where you're getting most of your growth from?

Reshema Kemps-Polanco
Chief Commercial Officer, Novartis

That's where we see a significant continued growth opportunity for Kisqali. There is a fair amount of them. I believe the last time I looked at the data, because it is growing every month, I would say it's a bit over 50% of the patients continue on monotherapy. I have to go back and check that, but I know it's definitely over 50%, because that's why I said there's quite a bit of headroom there. Again, I think that will be the contested space, but for all the reasons I stated earlier, the durability, the patient experience, the persistency that we're seeing, and just the sheer evidence and time, I continue to believe that we will continue to advance the CDK4/6 class there, and it sure should break our way.

Shreeram Aradhye
Head of Development and Chief Medical Officer, Novartis

All right. With that, I think we come to the end of our oncology session. Thank you for your attention. Take care.

Victor Bultó
President of U.S., Novartis

Good afternoon, everyone, and thank you for joining the neuroscience session. For those who I have not the chance to meet yet, my name is Victor Bultó. I'm the Novartis U.S. President, and I'm here with my colleagues from the neuroscience team. We have Nazem Atassi, who is the Head of Development for Neuroscience, Bob Baloh, who is our Head of Biomedical Research, as well in Neuroscience, and Renato Carvalho, who used to be our Head of Neuroscience for International, now taking over a new role as the Country President for Japan. If you don't mind, before we jump in into your questions, I just wanted to take a second to contextualize our strategy in Neuroscience and frame it for all of you. In a nutshell, we're building in Neuroscience from a position of real strength, both leadership in multiple sclerosis, pioneering work in neuromuscular diseases.

And now, the aspiration and the ambition that we have is to build on that leadership in MS and neuromuscular disease, and also selectively add our presence in the neurodegenerative space. Now, if we go into those of these three sections a little bit more in detail, in multiple sclerosis, we have been researching, developing, and commercializing multiple sclerosis medicines uninterruptedly since 2009. So we have accumulated a wealth of expertise, both in research and development, but also commercial presence, that has led to multiple successful launches, and Kesimpta being the latest one. As you could saw today, we upgraded our guidance to $8 billion globally on the basis of that very strong performance across international markets in the U.S.

We have now read out two phase III positive trials in RMS for remibrutinib, who we believe is a BTKI inhibitor, which is a class on its own, given how differentiated it is. We are running now a trial as well with remibrutinib in secondary progressive MS. So that is the pillar in multiple sclerosis. In neuromuscular diseases, we are working and building on the expertise that we have developed through SMA, with Zolgensma and ITVISMA, and then broadening very substantially our ambitions in the space with programs ranging from diseases like Duchenne muscular dystrophy, myotonic dystrophy, FSHD, and Charcot-Marie-Tooth, using a range of different technology platforms that Bob will elaborate on further, I am sure, later today. Then in the neurodegeneration space, we are looking to be very thoughtful and selective into which areas we want to step into.

Areas predominantly that share, on the one hand, very high unmet need, typically diseases that do not have approved therapies today. Also, where the biology is well-known, so that our researchers have a strong basis to start working on. Then thirdly, where one of our key technology platforms, be it splicing modulation or gene therapy or others, can be applied at generating a differentiated asset in the space, right? A good example of where those three intersect would be Huntington's disease, for example, where initially we had an asset developing in-house called branaplam. We took the learnings from that license, votoplam, and now we have phase II data and a phase III trial ongoing in the disease, right? That is a good example of how we look at this third area of neurodegeneration.

So in a nutshell, building on leadership and expertise in multiple sclerosis, in neuromuscular diseases, and also an ambition to broaden our presence selectively in neurodegeneration. With that, I will open it up for questions. Yeah, Florent.

Florent Cespedes
Analyst, Oddo BHF

Thank you very much. Florent Cespedes from Oddo BHF. Two quick questions. First, on remibrutinib in MS relapsing-remitting, as you have now the full set of results, and it should be on the market next year. Could you share with us how you see the ramp-up of the product in the U.S., given the profile and the competitive landscape and the experience you have in this field? My second question is an easy one. The Alzheimer's disease phase I project, could you tell us what is the mechanism of action or give us a little bit more on this one? Thank you.

Victor Bultó
President of U.S., Novartis

Thank you very much. Maybe I will start with that last question, Bob. More generally, because it is an undisclosed mechanism, of course, but more generally, how are we thinking about Alzheimer's disease as we tackle the next steps here?

Bob Baloh
Head of Biomedical Research of Neuroscience, Novartis

I think you summarized it well in your introduction in a way, because we try to look at where the biology is most well understood, where the modalities we have can target that biology, and then where clinical developability is coming together. I joked in one of the earlier sessions that it is always the decade of the brain. That is partly true, because it has been the decade of the brain for several decades, but that has often been about the biology. What we are really focused on is the technologies to target that biology. In the case of NIO752, which I believe is the one that you are looking at there, right? This is a tau antisense oligonucleotide, and it is the same molecule that is in phase III, actually, for progressive supranuclear palsy above it.

But in general, I think we see a lot of optimism, I will end on that, in the space because of the other piece, which is the clinical developability. So we have also seen biomarkers in the space that allow us to make good decisions on whether these assets and novel approaches that we are taking in the disease are altering the biology at a relatively early stage, so that we can then make good decisions about what to bring into much larger phase III trials and bring forward to Nazem. I mean, in a summary, yeah.

Victor Bultó
President of U.S., Novartis

Thank you very much. To answer the question on Remi, I would like Nazem to comment on how we are seeing the profile of the drug, how we are thinking about the submission as well, and then Renato and I will tackle the question on the uptake.

Nazem Atassi
Head of Development of Neuroscience, Novartis

Happy to talk about remibrutinib anytime. You look at it from both the efficacy and a safety profile of the medicine. Let us start with the efficacy profile. We had two large phase III trials. Each has 1,000 patients approximately in relapsing multiple sclerosis. If you look at every trial separately, each trial hit its primary and all the secondary endpoints for the trial itself. That is the annualized relapse rate as a primary, all the MRI endpoints as secondary, and the neurofilaments as a key secondary as well. Both of each trials independently hit on all of the primary and the secondary. Then you have the pooled analysis. The pooled analysis looks, and that is obviously pre-specified pooled analysis. You look at the data from both trials together, and that pooled analysis, the first one in the hierarchy is the three-month confirmed disability progression.

The second one is the six-month confirmed disability progression, and the last one is the NEDA, which is no evidence of disease activity, which means that there is no relapse, no MRI, and no progression in that group of patients. Out of these, it hit on all of them except for the first one, which is the three-month confirmed disability progression. On the relapse rate, I always say that remibrutinib was able to be superior to the best perform that teriflunomide had ever in any other trial. You have very, very low relapse rates in the remibrutinib arm, in the order of one relapse every 13 years, which is quite impressive, I would say, for this population.

The other thing is we saw a very good result on the MRI, 70%-75% reducing the MRI. Then we saw neurofilament reduction as well in each of these trials. The three months and the six-month confirmed disability progression, I will just explain the difference between these two. The three months confirmed disability progression means that you have a progression of the disease that is recorded, and then you have to confirm it three months later. If it confirms, then that is an event for that three-month confirmed disability progression. The six-month, exactly the same, but then you have to confirm it six months later. What we saw is 20% reduction in the three-month confirmed disability and 30% reduction in the six-month confirmed disability. What does that mean?

That means there is a subset of patients that had a relapse, that they had a progression for three months, that actually improved by itself, did not make it to the six month. That is why we have more events on the six month, and that is why you see more. So, six months represents the sustained effect of the drug when it comes to the disability. We also, since we believe the disability, and that is what we heard from most of the KOLs that we talked to, when you have now medicines with relapse rates in such a low rate, the real focus is on the progression of the disease. That goes back also to the mechanism of action of this medicine.

This medicine works both in the periphery and centrally, works on B cells in the periphery, on the acute inflammation, on the relapses, and works centrally on microglia, on the chronic progression of the disease. We did a PIRA analysis, which is a progression independent of relapse analysis, which means that you have progression that usually is either associated with a relapse, so patients will have a relapse, will never recover back from the relapse, and that is considered progression related to relapse. But patients also continue to progress independent of relapses. This analysis takes out these relapses and then looks at what is left over from the progression, and we saw a 30% reduction in confirmed disability progression. We believe that this medicine offers a comprehensive disease control, both on the acute and the chronic, the relapses, and then the progression.

Now, when it comes to, that is on the efficacy side. When it comes to safety, we look at remibrutinib as a class on its own when it comes to safety. That is also by design. This medicine has a different chemical chemistry. This medicine has a very selective profile when it comes to the kinase inhibition among the class. It is by design very different than the other BTKIs, and that translated to what we have seen in clinic as well. Not only in the MS trials, which I will touch on, but also across all the indications that we have for this medicine. Remember that this medication is already on the market for 25 milligram BID dose for CSU and others. For that, we have over 15,000 patients treated, and we have not seen any safety, liver-related safety. That is usually the question for this.

But also, we had 4,500 patients that were treated across different clinical trials with dosages up to 600 milligrams with this medicine. Then, of course, we have the RMS data with the two trials that we finished. In that, you would see, if you compare the active control arm, which is the teriflunomide, to the remibrutinib arm, you will see that there is a comparable rate of infections between the two groups. You will see actually a lower rate of discontinuation due to adverse events in the remi arm compared to teriflunomide arm. Most importantly, we do not see any liver signal whatsoever. So, no Hy's law cases, and no liver signal. That is validated by all of these numbers that I gave you about how many patients been exposed to this medicine.

We really believe that on a safety profile, this compound is very differentiated, and it is a class on its own when it comes to safety.

Florent Cespedes
Analyst, Oddo BHF

In terms of ramp-up for-

Victor Bultó
President of U.S., Novartis

Yeah, so in terms of ramp-up, we have guided to this being a $4 billion + opportunity in RMS on the basis of three main patient populations where we see there is a substantial need, right? The market, on the one hand, you could argue that the market is really well served with B-cell therapies like Kesimpta, right? However, there is a number of patient populations where we believe the need is salient and that will contribute to that peak, but also to the uptake. First is, about 30% of patients who are naive in this market start with something else than a B-cell therapy, right?

We believe the majority of these patients will continue to start with a B-cell therapy, but for that 30% who do not want to be on a B-cell therapy, who do not want to be on an injectable, who are choosing an oral therapy, this is going to be a very strong value proposition and a strong uptake from that perspective. Then we have about 60,000 patients in the U.S. today who are currently treated with an oral therapy, right? About 20% of them switch out every year, but we believe, based on claims data, that about half of them are actually not well controlled on these oral therapies. They may be sticking to their therapy just on the basis that it is an oral therapy, or either maybe they have concerns on B-cell depletion on longer term.

And then there is a third category that will contribute to this, which is the post-anti-CD20 patients. We are running a trial, a phase IIIb trial right now, that is investigating that switch out from ocrelizumab into remibrutinib in patients who have been treated with a B-cell therapy for a period of time and above a certain age, because that is a period when concerns about long-term B-cell depletion start emerging, and/or there is disability progression that starts showing up, right? When you take these three populations, two key takeaways. One, salient need that is actually not overlapping with the use of a B-cell therapy, and secondly, very large populations, right? That is why we are committed to that uptake, and we are very optimistic about the performance of the drug. Yeah, Steve?

Steve Scala
Analyst, TD Cowen

Thank you. Steve Scala from TD Cowen. Two questions. At this meeting last year, the company said it was having internal discussions about evaluating its cardiovascular assets in the treatment of Alzheimer's disease, and I am wondering if those discussions ever went anywhere. This admittedly was before the semaglutide readout in Alzheimer's. The second question is more big picture, but I have to say, I question your strategy in this area. The pipeline is narrow and focused. Victor, you set the criteria for entry into new areas of neurology as unmet need, so that would presumably be all neurological diseases, that you understand the biology, so that would be no neurological disease, and that you want to be selective. But why? Why not make a major statement and go into a broad number of diseases, maybe through M&A?

The company strikes me as being risk-intolerant in this area, with all due respect. That is my question.

Victor Bultó
President of U.S., Novartis

Oh, thank you very much, Steve.

Bob Baloh
Head of Biomedical Research of Neuroscience, Novartis

I find that refreshing, actually, because usually people think this is the most difficult area and that we're taking too many risks. I mean, look, maybe I'll speak a little bit to the neuromuscular pillar. I mean, look, this is an area where we think in each of the diseases that's listed on the chart there, we understand the fundamental biology. We generally know the gene that causes the disease. They're monogenic. They're the five most common inherited neuromuscular diseases, so they all have a lot of patients with a lot of unmet need, perhaps with the exception of SMA, of course, which has several therapies and a place that we've been a leader. I think there, the science is extremely well understood. So, I do argue with that and since there.

Of course, there are still challenges, as we've run into, but matching those with the modalities that we have now, and we look at it as genetic medicines broadly. So obviously, we've been successful with gene therapy, but we've pushed very hard into antibody oligonucleotide conjugates with the acquisition of Avidity last year. And we still have a lot of faith in that platform. I mean, we've seen really good success, we believe, in the del-zota case, for example, where clearly we're delivering to muscle effectively. We are augmenting the level of dystrophin to levels that really have not been seen before in that condition, and having impact on the CK levels, also really not unprecedented in that condition. So we know that that platform can deliver. We're seeing similar things from del-brax, and we'll talk about perhaps the other programs.

And of course, del-desiran, while it did have challenges in its phase III program, we will talk about, we have clear evidence of signals of biological activity, and we think the platform can deliver, and we want to move that program forward. Across that space, then together, EDK060 on there, one of my favorite programs, fatty acid conjugated siRNA to PMP22, and the disease which is actually the most common inherited neuromuscular disease of all of these, Charcot-Marie-Tooth disease type 1A. We're leading in that space as well. And then these two other gene therapy programs, which are building as this Kate acquisition from a few years ago, you may recall, which we really think will define the next generation of gene therapies with a profile of being able to deliver very specifically to on-target tissue, detarget liver, and be at a lower dose.

I mean, of course drug development is hard. I think it's a difficult point to argue with in some sense, but we go in acknowledging that and trying to take all of those things, bring them together. I think that cluster's outstanding. Now, Alzheimer's disease, maybe talk to that, right? That lower cluster is more difficult. I mean, I'd struggle to think of how we're being too risk-averse versus not. I mean, one has to balance the investment, and what I think what we're trying to do is to advance the programs logically using biomarker-driven phase II designs, which we talk about, and maybe I can pass to you in a moment, to test as many mechanisms as you can, because there we don't know the, usually, in these sporadic versions, the key underlying gene that we need to target.

We do need to explore a little bit more space. Our approach is to explore that space, hitting these major targets. In Alzheimer's, APOE, A-beta, neuroinflammation, and tau, of course. But then also to couple that with logical designs to test these ideas early without what we used to have to do, which of course, to go into very large phase IIIs. But maybe to pass to Nazem, on that theme, do you want to build on?

Nazem Atassi
Head of Development of Neuroscience, Novartis

I mean, I am happy to say a couple of words. I mean, you covered it really nicely. I mean, if you look at the biology of most of these diseases that we are looking at, it is very well understood. Most of them are monogenic diseases where we know the gene, we know the protein, and we are targeting that gene or that protein. So, including Huntington, on the neurodegeneration pillar is with Huntington protein. Even looking at PSP, it is a primary tauopathy, so we have seen data that suggest that tau, targeting tau production in Alzheimer's could be beneficial. So this is even more, this is a primary tauopathy. So, I think from a biology perspective, we have been very selective in a good way, selective.

On the phase II trials, if you look in the past 10 years, things have shifted drastically when it comes to drug development, neurodegenerative disease, especially on Alzheimer's, because of the biomarkers, because of the imaging tools, and because we also understand these diseases better in terms of the populations. The earlier you go, the more success you have. So now, we have proof of concept for A-beta targeted therapy. So, you know if you lower, for example, amyloid in the brain to a certain extent, you know approximately what to expect from a clinical effect. We started to see the same thing for tau, one of the targets that you mentioned as well. And neuroinflammation, I think, will follow suit. So, I think we are in a much better place. It is the decade of neurology, I think neuroscience, this is this decade.

Victor Bultó
President of U.S., Novartis

Thank you very much. Yeah. Sachin.

Sachin Jain
VP, Bank of America

Sachin Jain, Bank of America. Could we touch on the two Avidity assets? You talk about DM1, seeing signs of activity, so your phase III. Perhaps you could just give us some sense of what we should look at when we look to the data, and what timelines are we thinking about for the phase III? Then FSHD, if you could just clarify the level of comfort you have with the FDA conversation on accelerated, and what exactly has driven the push-out, and perhaps the trial design changes that have extended the study and new endpoints. Thanks.

Victor Bultó
President of U.S., Novartis

Great. Thank you. Naz.

Nazem Atassi
Head of Development of Neuroscience, Novartis

Yeah, so both of them use the Avidity platform, which we are very excited about. I will start with DM1, and then I will talk about FSHD. The DM1, as Bob mentioned, we know that this siRNA gets to the muscle, engages the target with target engagement. That was the phase II study. We saw vHOT changes in the phase II study and some clinical trends as well.

Now, we ran the phase III trial, and the vHOT was the primary endpoint of that phase III trial. We did not see the same signal that we saw in the phase II in vHOT. But when we looked at the secondary and the exploratory endpoint, we see clear clinical trends and clinical benefit on a number of endpoints that we looked at. So, what we have done is that now we are looking at the phase III trial data that we have.

It's a wealth of data. We are also looking at the open-label extension. Most of these patients continue to be dosed in the open extension period, and we're collecting data on both. We're looking at the data from both, they collected from the open label and also that it's currently in the phase III trial. We're looking at dosing interval, we're looking at trial design, we're looking at sub-populations, and we're looking at the endpoints. We're looking at the endpoints on how to acquire these and standardize acquiring these endpoints, how to standardize scoring these endpoints, how to standardize analyzing these endpoints, all of them, not only vHOT.

The goal is to get to an optimized trial design with optimized endpoints and take that to the FDA and have a discussion with regulators on the next proposal phase III, second phase III trial, and get their agreement on the next steps for that phase III trial.

Victor Bultó
President of U.S., Novartis

You want to comment on FSHD as well?

Nazem Atassi
Head of Development of Neuroscience, Novartis

FSHD. So, that's del-brax. On FSHD, again, this is a neuromuscular disease that is progressive, irreversible, affects muscles in the face, arms, and legs. It's a very disabling disease. I've seen a number of patients with this condition in my clinical work. So, the del-brax also goes to the root cause of the problem. It goes at the DUX4 gene, which causes FSHD. The readout that we get out of that is the downstream effect on KHDC1L, which is downstream gene from the DUX4. So, the phase II data that we have from cohort C, which is the same dose and same dosing schedule that is currently in the ongoing enrolling phase III trial.

When you look at this data, you would see, I mean, it was presented by Vas this morning, you would see a clear reduction, 50% reduction in the biomarker in KHDC1L, which it tells you it's a marker you get from the blood. It washes out all the information that is coming from all the muscles, and it gives you that number. Then you have the CK, which is even more downstream, that tells you on muscle health and muscle protection. We see a pretty significant reduction in the CK level, 30%, which gets close to the normal levels in these patients. We've seen also some clinical trends as well. Considering that this is a big unmet need, a disease that has no medicine approved for it, we took all of this data and we had a discussion with the FDA about an accelerated approval.

In that discussion, the FDA looked at the data. They were encouraged about the data, but they also recognized that this is a slowly progressive disease, and one-year data that we presented to them, that's the data that we had from the cohort C, was not long enough to show a separation or show a big progression, actually, in the patients, and especially in the placebo arm. For that, we left it open. We left the door open that we will look at the 24 months data, the two-year data next year from that ongoing study, and then we'll engage with the FDA based on the results of that data. That's on the accelerated approval. We also proposed a few changes to the ongoing phase III trial. The endpoints is already being collected. The trial design obviously does not change.

We made the trial a little bit longer, and we made it a little bit bigger, and the idea is to make it a more robust data. This is informed by the data that we learned from the cohort C population and also looking at some external controls as well, natural history data.

Sachin Jain
VP, Bank of America

Do you expect the clinical data to shift materially from year one to year two in the ongoing-

Nazem Atassi
Head of Development of Neuroscience, Novartis

It's a slowly progressive disease, but obviously, you see double. I mean, if it's linear, you would see double whatever you saw initially. You would double that if everything is linear in the second year. Yes, we expect-

Sachin Jain
VP, Bank of America

You expect about how much you saw at year one on the clinical endpoint?

Nazem Atassi
Head of Development of Neuroscience, Novartis

We will present this data at a conference next year. You will see everything. You will see not only the data that you saw today that Vas shared on the biomarkers, but also you will see the clinical data as well.

Victor Bultó
President of U.S., Novartis

Thank you, Graham.

Graham Parry
Analyst, Citi

Thanks. Graham Parry from Citi. A couple on Remi. Just in terms of what you would expect on the label, the six-month CDP data was nominally significant, and the PIRA, I think, was a post-hoc analysis. Just your confidence in being able to have that reflected in the label somehow, and otherwise, how would you differentiate the asset? Second would be your confidence in not having liver monitoring on the label at all, given it was included in the trial. Third, excuse me, is on the SPMS opportunity. I think you flagged, Victor, in the slides, is 85,000 diagnosed patients globally, but one of the things we often hear is that these patients are not diagnosed because if you get a diagnosis, you do not have a therapy, so they just keep patients on the relapsing product.

Do you have a sense for what proportion of the market actually might be as SPMS, and could that actually be a material upside to Remi sales over time? Thank you.

Victor Bultó
President of U.S., Novartis

Great. Well, thank you very much.

Nazem Atassi
Head of Development of Neuroscience, Novartis

Yeah. I will start with the progression question. As I mentioned, the progression data is very consistent, and it is very robust when you look across all the progression measures that we looked at. The three months, although did not hit the p-value for statistical significance, it is 20% reduction in that measure. The six-month confirmed disability progression shows 30% reduction, and the PIRA, which is independent of relapse, shows also a similar 30% reduction. Considering the consistency, and it is just a matter of hitting the p-value or not, and also considering that the six month is a more robust way and actually more conservative way to look at the real progression rather than the noise. I mean, three months obviously has some noise because some patients did improve.

We believe that this is strong enough data to give us a strong position when we negotiate that with the FDA. It will be a matter of negotiation and see what ends up in the label. But again, I think we are in a strong position to present that data because of all of these factors, the consistency and the level of signal that we've seen. It's not one that it's positive and everything else goes in the other direction, for example. So, that's for U.S. For Europe, the EU, they prefer to look at the six-month confirmed disability progression more than the three-month confirmed disability progression. So, we are even at a stronger position because that's really what they would like to evaluate because of it's more confirmed, it's more sustained signal. So, that's on the progression.

In terms of the liver label, I will reiterate, we did not see any liver signals whatsoever, no Hy's law cases in this trial or in any other trial or patient who took this medication on the market or in any other trial. In fact, if you look at the trial result, you would see a small percentage of patients who had 2%, there's a 2% of patient had a little bit of increase in ALT in the Remi arm. If you look at the placebo arms of MS trials that were conducted, some of them are recent, like the tolebrutinib trials, and some of them are older, you will see that there is a background increase in ALT. In fact, even in healthy volunteers, in all of us, our ALT is very dynamic. It goes up and down.

So, that number is somewhere between 1.5% and 4%, and we are in the low end of that background noise for this. So, we feel very confident about the safety profile of this medicine. So, without any liver signal, neither on the lower dose or this dose or on the market, and also having already a clean label with no warnings and no black box, no monitoring requirement from the CSU, we believe that we will maintain the CSU label with no monitoring in this trial. Of course, we did monitor in the Sorry, no monitoring in the label. Of course, we did monitor in the trial, as so we did in the CSU trial. We did monitor in CSU trial. So, having monitoring in the trial does not translate that you need to do monitoring on the market in clinic.

I hope that gives you a sense of where we stand on the safety profile.

Victor Bultó
President of U.S., Novartis

Yeah. Thank you, Nazem. On the secondary progressive MS, Graham, you are spot on. This is a conservative value on the basis of well-defined diagnosis. As you know, even the difference between relapsing, non-relapsing SPMS, it is kind of blurry. My take, and Renato, I do not know if you see it differently for international, is the better results we show, the more patients will emerge, right, in terms of progression, right? This is clear, the next frontier, the real unmet need right now in multiple sclerosis is in progression. We are very encouraged by the data that we saw, again, very consistent across three months, six months, PIRA, and NEDA, right? If that were to translate into SPMS, we believe we have a very substantial addition to the estimates that we have for the brand. I do not know, Renato.

Renato Carvalho
Country President of Japan, Novartis

Yeah, the same thought for international. We do believe on the same direction. We have been having conversations with HCPs in the community, and everyone is on the same page as us. We do believe that we are being somehow realistic but conservative as well. We have an opportunity to go beyond what we have been assessing so far.

Victor Bultó
President of U.S., Novartis

Thank you.

Pete Verdult
Analyst, BNP

Thank you. Pete Verdult, BNP Paribas. Two questions, maybe for Bob, if I am correct, earlier on, did you call out unprompted EDK060 as the asset? What was the asset you said that you were really excited about?

Bob Baloh
Head of Biomedical Research of Neuroscience, Novartis

Yeah, that's right.

Pete Verdult
Analyst, BNP

Well, I'd love to hear more about that because that's not an asset-

Bob Baloh
Head of Biomedical Research of Neuroscience, Novartis

Sure.

Pete Verdult
Analyst, BNP

That I think is on the market's radar. Just what gets you excited, next steps, anything you're willing to share at this stage? That's question number one. Then a bit more boring for you, Victor. I know that Novartis have assumed that Kesimpta goes with the LOE, but you've got Q2M. Is there a life cycle management story here? I know you're going to assume the worst, but what can Q2M really do? Are you going to do on-body device, high concentration, just life cycle management opportunities for Kesimpta?

Victor Bultó
President of U.S., Novartis

Excellent. Thank you. You want to start, Bob?

Bob Baloh
Head of Biomedical Research of Neuroscience, Novartis

Yeah, glad to start. As I mentioned, when we looked at what our strategy should be in neuromuscular diseases, we looked at the most common ones. As Nazem pointed out, we've both taken care of these patients. I used to work in Muscular Dystrophy Association camp. I mean, these were the five types of diseases you would often see. We know that they're really common, and we understand what causes them. In this case, PMP22, peripheral myelin protein 22, is duplicated. If you have three copies of the gene, you form abnormal myelin. Typically what happens is you have that from birth, but then sometime during the first to second decade, you start to degenerate the axons, which go to the longest axons, go to your feet, then your legs, then your hands. It's a progressive neurodegenerative disease, has absolutely no cure.

The only treatments are ankle-foot orthoses so that people don't break their ankles. They tend to have surgeries to sort of fix deformities. That's basically it. We thought this was a really strong area to apply siRNA technology, and we acquired DTx Pharma a few years back, and this was the main asset that came from that acquisition. Vas mentioned this as well in his talk. This is a bit distinct in that it has a fatty acid conjugate for cellular delivery. What we found is that that's actually quite effective at delivering to Schwann cells. These are the cells that form the myelin around the peripheral axons. This is in phase I right now.

It's too early to give more exciting data than that, but we're clearly excited about it because it fits the strategy, it fits the platforms that we're interested in, and it's a huge opportunity for those patients.

Victor Bultó
President of U.S., Novartis

Thank you, Bob. In terms of Kesimpta, as you all know, we're developing an every two months formulation right now, and the objective is really patient convenience there, right? We don't expect to have additional IP from this formulation, but we do expect a proportion of patients to be switched over time, given their preference to this every two months formulation. In terms of LOE, we continue to guide to the composition of matter, which is in 2031, as you pointed out. Of course, some additional patents, secondary patents, there, and we will do, as we always do, our job in defending them, but we continue to guide to that composition of matter, 2031, as a key timeline.

Now, in terms of erosion, as you know, it's multifactorial in terms of how many biosimilars may get approved by the time of that LOE, but also how does biosimilar utilization, substitution, and other regulations evolve over time from now to 2031? I'll come to you.

Speaker 13

Holger Blum from [Bellevue Asset Management.] My question goes to clinical trial conduction. In a way, now MS patients are more lucky to have more choice. Why did you choose AUBAGIO, which is generic by now, as a direct competitor in the trial? Wouldn't it be more meaningful to go after the market leader? Or back in the days, did you underestimate the profile you got finally in your hands with Remi?

Victor Bultó
President of U.S., Novartis

Thank you very much.

Nazem Atassi
Head of Development of Neuroscience, Novartis

Would you like me to take this one?

Victor Bultó
President of U.S., Novartis

Okay.

Nazem Atassi
Head of Development of Neuroscience, Novartis

Yeah. I mean, remember when the Remi trial started, it didn't start today. It started a long time ago, six, seven years ago. Up until recently, up until now, I would say that AUBAGIO has been the standard. If you look across the board, different trials, actually all the BTKs, you would see that AUBAGIO has been, or teriflunomide, has been the standard oral treatment that you compare against. AUBAGIO now, teriflunomide, we look at it now as that we have a lot much better treatments compared to teriflunomide. But when you look at that time, actually, it was a pretty good treatment and had good results. Based on that, it somehow became the standard for the MS trials at that time.

Victor Bultó
President of U.S., Novartis

Now, having said that, it's an interesting debate, for example, at MSToronto recently, on whether this is going to be the last trial, phase III trial we see with teriflunomide as a comparator, because as the selection bias comes in, I mean, of course, in the newer trials, milder patients are recruited because there's a chance that patients will be treated with a teriflunomide arm. You see the activity in those trials coming so low that it's actually become a very high bar to beat teriflunomide in that patient population. There's a whole debate in the field. It's a very pertinent question for the trials that might start moving forward.

Nazem Atassi
Head of Development of Neuroscience, Novartis

It's interesting that you look at the teriflunomide performance across the trials over the past seven, eight years, and teriflunomide's been getting better and better and better. Of course, it's not. It's the selection of the population that we're enrolling in our trials. They're becoming less and less active as they come in.

Victor Bultó
President of U.S., Novartis

Thank you. Can we get a mic there? Thank you.

Simon Baker
Analyst, Rothschild

Thank you. Simon Baker from Rothschild. Two for me, please. Firstly on votoplam. You showed in the phase II data very significant reductions on HTT levels. What is your confidence on showing a clinical effect in phase III, given the work that was done last year on CAG repeat accumulation? Secondly, on Zolgensma, and more broadly on gene therapy, the FDA flagged last month about the possibility of AAV incorporation in oncogenes. What are your perspectives on that from a Zolgensma perspective, because we are talking, what, nine in 6,000 cases. What does that mean more broadly for gene therapy?

Victor Bultó
President of U.S., Novartis

Thank you very much. So, you want to take this?

Bob Baloh
Head of Biomedical Research of Neuroscience, Novartis

Well, the first one was the votoplam question, right?

Victor Bultó
President of U.S., Novartis

Yeah.

Bob Baloh
Head of Biomedical Research of Neuroscience, Novartis

Yeah, I think votoplam is built off of our knowledge in a sense, and the discovery of branaplam, which many of you may remember from a few years back, which was a molecule that also altered the poison exon inclusion in Huntington, but it had some neurotoxicity findings. We, based upon those learnings, a deep understanding of the safety profile in the entire class, did the partnership with PTC. Obviously, you have heard about the phase II results. We know the phase III trial is ongoing. I will let Nazem speak to that in a minute. I think what you are speaking of is the additional evidence that CAG expansions take place during disease or that there are other mechanisms. I think

Simon Baker
Analyst, Rothschild

It's this idea that you get above about 30-

Bob Baloh
Head of Biomedical Research of Neuroscience, Novartis

Yeah.

Simon Baker
Analyst, Rothschild

36- 50 CAG repeats and then you just-

Bob Baloh
Head of Biomedical Research of Neuroscience, Novartis

Exactly, right. You started in the 30s, right? But the idea is coming out in the literature when you look at human tissue, as well as human genetics, that things that lead to more rapid somatic expansion of the CAG repeats are also contributing. So actually, one way to think about it is both of those are at play. If you hit Huntington itself, you still should have an impact on the disease. I think the fundamental hypothesis, therapeutic hypothesis, still stands for Huntington lowering. I think what it starts to open up is in the future, potentially adding additional mechanisms on top of that to get more clinical benefit. But maybe Nazem, if you want to speak to the-

Nazem Atassi
Head of Development of Neuroscience, Novartis

Yeah. Yeah, yeah. I'm happy to speak. Remember that none of these happening at the switch, not one day that all the Huntington, mutated Huntington, and all the expansions are happening. Its cells are happening at different times in the disease. So maybe a few words on votoplam. It's an oral splice modifier. We had the phase II data. We looked at the 24 months data recently. I believe it was shared as well. So the 24 months data shows that the patients in the first 12 months, that's double-blind period, you show a reduction in Huntington protein compared to placebo. Then the patients who switched from placebo to the open label, you see a similar reduction in Huntington, and then that was sustained across the 24 months. So that gives us confidence that we're hitting the target.

In terms of the clinical data, if you, I think Vas presented it, showed the data this morning. If you look at the 24 months data for the treatment for the patients who were treated with the 10 milligram, you compare that with an external control arm. You would see about 50% reduction in the rate of progression in the patients treated with the 10 milligram compared to the external control arm. I would like to clarify that this external control arm was very well selected. It was selected based on eligibility criteria. On top of that, it was the propensity scores and other statistical methods to reduce the impact of a placebo effect. This is a very conservative way to look at the data.

But of course, the error bars are large. This is exploratory. This is a phase II study that is not powered to look at clinical efficacy with any p-values. But that gives us confidence about this molecule, both in terms of hitting the target and also seeing the clinical trends. Because of that, considering how devastating this disease is, this is an autosomal dominant disease, runs in families, really, really devastating. There is no available treatment that stop, reverse, or slow down this disease. We would like to bring this medicine to patients as quickly as possible. We did request a meeting with the FDA. We have the meeting in Q1 2027 to explore the path for an accelerated approval based on the data that we already have, the 24 months data from the phase II study.

Victor Bultó
President of U.S., Novartis

Thank you. Nazem, do you want to touch on Zolgensma and more generally-

Nazem Atassi
Head of Development of Neuroscience, Novartis

Yes.

Victor Bultó
President of U.S., Novartis

As well on our approach to gene therapies? With that answer, we will have to close.

Nazem Atassi
Head of Development of Neuroscience, Novartis

So maybe I'll set up for ZOLGENSMA, and you can talk about the other gene therapies. ZOLGENSMA has been approved for many years now. We have treated over 6,000 patients with this life-changing medicine. There's a number, a handful of reported tumors in this population. Of course, we've been sharing these cases with health authorities across the globe in real time, in a transparent fashion. Some of these were included in the label in 2023. We've had in the label, in the precautions, that there is a potential, a theoretical risk of tumors. This is based on a known fact that there's a small percentage of this vector genome does incorporate within the host, within the patients. We knew that this risk was there, but we did not understand that risk as much.

Then there's two cases where there was mentioned in the FDA post that they put last week on their website, where the integration is. The question is where the integration is happening, and in these two cases, it's happening in an oncogene or close to an oncogene. So that establishes more relationship between the treatment and, at least in these two cases, the tumor. We're working very closely with the FDA. It's clear on their initial assessment on their website that the benefit risk, the benefit outweighs the risk, again, in this life-changing medicine. We're working very closely with them for any potential changes in the label or changing the language in the label.

Victor Bultó
President of U.S., Novartis

Right. Bob, you want to answer the question on how is that-

Bob Baloh
Head of Biomedical Research of Neuroscience, Novartis

I mean, I'll have to cover it quickly, right? Because, we're obviously dedicated to innovating in this field. We've been sort of changing the characteristics of the capsids, the payloads, and all of these pieces for many years now. The two medicines which are going to enter into the clinic, hopefully next year, one of them already IND approved, DLW196 for FSHD, GZP841, are an example of that, what this next generation of gene therapies needs to look like. I mean, whether we will be able to mitigate the risk of rare or ultra-rare events of DNA inserting into the genome, we just don't know yet. We really do need to learn from these cases as we get more and more information and see if those things are something that can be addressed or changed. But as you said, we have some pretty exciting programs coming up.

We're really bringing them forward next year. Anyhow, wanted to just finish on that.

Victor Bultó
President of U.S., Novartis

Well, thank you very much. Thank you all for joining us. For those here in person, please, just a reminder that you can join us in the main room, Danziger, for the AI panel. Thank you very much.